Saint Louis University Law Journal
Volume 56
Number 2 (Winter 2012)

Article 5

2012

Reassessing Safety for Nanotechnology Combination Products:
What do Biosimilars Add to Regulatory Challenges for the FDA
Jordan Paradise
Seton Hall University School of Law, paradijo@shu.edu

Follow this and additional works at: https://scholarship.law.slu.edu/lj
Part of the Law Commons

Recommended Citation
Jordan Paradise, Reassessing Safety for Nanotechnology Combination Products: What do Biosimilars
Add to Regulatory Challenges for the FDA, 56 St. Louis U. L.J. (2012).
Available at: https://scholarship.law.slu.edu/lj/vol56/iss2/5

This Article is brought to you for free and open access by Scholarship Commons. It has been accepted for
inclusion in Saint Louis University Law Journal by an authorized editor of Scholarship Commons. For more
information, please contact Susie Lee.
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REASSESSING SAFETY FOR NANOTECHNOLOGY COMBINATION
PRODUCTS: WHAT DO BIOSIMILARS ADD TO REGULATORY
CHALLENGES FOR THE FDA?

JORDAN PARADISE*
ABSTRACT
Amidst sweeping changes to the United States health care system ushered
in by the Patient Protection and Affordable Care Act (“ACA”), the Food and
Drug Administration (“FDA”) continues to struggle to apply often centuriesold product categorizations to emerging technological innovations. The
ACA’s introduction of a “biosimilar” pathway to market for biological
products, modeled on abbreviated pathways to market for drugs and medical
devices, further complicates the assessment of “safety” and measures of
equivalence and similarity that allow products to enter the market faster. One
area where this is particularly acute is nanobiotechnology, which has enabled a
set of products that drift uncomfortably at the interface of drugs, medical
devices, and biologics, blending unique and novel biological properties at the
nanoscale that integrate chemical, mechanical, and biological aspects into a
wide range of consumer medical and health care products.
This Article will argue that the creation of the biosimilar pathway will
prove to be the straw that breaks the camel’s back unless the FDA develops
new dynamic models to properly assess and regulate nanomedical combination
products. This Article will examine the existing frameworks of FDA oversight
for medical and health care products, highlight nanotechnology (and
nanobiotechnology and nanomedicine) specifically as an area where products
are currently straddling traditional boundaries between FDA product
categories, discuss recent FDA initiatives and Agency procedures regarding
nanotechnology, and will suggest an approach for the FDA to respond to
nanobiotechnology, including more effective federal coordination;
reorganization of the FDA either through congressional action or
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Commissioner action in order to properly classify, assess, monitor, and
regulate emerging nanomedical technologies and products; and changes to
FDA policy regarding data requirements and post-market reporting from
industry to address concerns about the scope of safety in the context of
nanomedical products.
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INTRODUCTION
The Patient Protection and Affordable Care Act (“ACA”)1 brought
sweeping changes to the U.S. health care system, triggering immediate
challenges to the constitutionality of the legislation and seemingly limitless
questions regarding its practical implementation. The ACA also ushered in a
new era for the oversight of biological products within the purview of the U.S.
Food and Drug Administration (“FDA”), creating a pathway for approval of
products that are “biosimilar” or “interchangeable” with an existing biological
product (“biologic”).2 In doing so, Congress has deposited a major regulatory
challenge in front of the FDA during a time in which the FDA faces daily
onslaught for its perceived inability to assure safety and efficacy of drug and
medical device products.3 This challenge is amplified by advancements at the
intersection of nanotechnology and medicine and health care, which pose novel
problems for safety assessment of drugs, medical devices, and biologics.
Product classification is a touchstone of regulation by the FDA. The
classification of a new medical advancement as a drug, medical device, or
biologic determines the FDA center to which it is allocated and therefore
which approval process it will follow.4 This, in turn, determines the financial
investment required to bring it to market and the extent and type of
requirements imposed on industry, particularly requirements governing
measures of safety to ensure that benefits outweigh risks for each product.
Each route to market has its own requirements and process and its own set of
ensuing controversies.5 Recent high-profile product recalls, outcry over
improper scientific data, and challenges to the adequacy of post-market
monitoring have plagued the FDA in the context of drug and biologic
oversight.6 Medical device oversight has similarly been subject to increased
scrutiny by Congress and the Institute of Medicine (“IOM”) with regard to the
FDA’s overwhelming use of the 510(k) clearance process rather than requiring
full-scale safety and efficacy review and approval.7 The FDA’s assessment
and treatment of scientific and technical information guides oversight of
product areas, dependent largely on sometimes-irrational categorical and

1. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010)
(codified in scattered sections of the U.S. Code).
2. Id. § 7002(b), 42 U.S.C. §§ 262(i)(2)–(3) (Supp. IV 2010).
3. See, e.g., INST. OF MED., MEDICAL DEVICES AND THE PUBLIC’S HEALTH: THE FDA
510(K) CLEARANCE PROCESS AT 35 YEARS 193 (2011).
4. See infra Part II.A–D.
5. See infra Part II.A–D.
6. See, e,g., infra Parts II.A, II.C.
7. See INST. OF MED., supra note 3, at 4; infra Part II.B.
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definitional divisions that structure the Food, Drug, and Cosmetic Act
(“FDCA”).8
Recognizing the swift integration of drug, device, and biologic elements in
medical and health care advancements, Congress created the FDA’s Office of
Combination Products (“OCP”) to assess emerging technologies at the
interface of these three product realms.9 The OCP classifies a product as a
drug, medical device, or biologic according to its “primary mode of action,”
directing it to the appropriate FDA Center and route to market based on this
determination.10 The combination product process itself faces ongoing
criticisms, flowing both from perceived shortcomings in the three product
classifications (drug, device, or biologic), and the resulting silo effect of the
FDA’s determination for products that integrate chemical, biological, and
mechanical mechanisms of action in often novel and innovative ways.11
Congress has now added yet another layer to the FDA’s regulatory
challenge with the enactment of the recent health care legislation. The
Biologics Price Competition and Innovation Act of March 201012 (part of the
ACA) creates an additional route to market for biologics—the “follow-on” or
“biosimilar” biologics approval pathway—and gives broad implementation
authority to the FDA.13 The creation of this biosimilar pathway, coupled with
the abbreviated pathways to market for both drugs (the abbreviated new drug
approval pathway) and medical devices (the 510(k) clearance process), and the
combination products mechanism, poses significant implementation challenges
for the FDA.
It is now useful to take one step back and ask: is the “combination
products” approach and availability of abbreviated routes to market the right
conceptual framework to assure product safety for new, category-busting
products? One area that highlights the effects of category confusion is
nanomedicine, the interface of nanotechnology with human health and
medicine, where emerging products promise to combine aspects of two or even
all three product areas. Utilizing scientific and technical properties of
nanotechnology, medical innovations are now pressing the traditional bounds
of the FDA’s product classification scheme, integrating multiple and dynamic

8. Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as
amended in scattered sections of 21 U.S.C.).
9. See infra Part II.D.
10. See infra Part II.D.
11. See, e.g., Susan Bartlett Foote & Robert J. Berlin, Can Regulation be as Innovative as
Science and Technology? The FDA’s Regulation of Combination Products, 6 MINN. J.L. SCI. &
TECH. 619, 622–23, 631, 640–41 (2005).
12. Pub. L. No. 111-148, §§ 7001–03, 124 Stat. 119, 804–21 (2010) (codified in scattered
sections of 42 U.S.C. & 21 U.S.C. (Supp. IV 2010)).
13. 42 U.S.C. §§ 262(k)(8)(A)–(B) (Supp. IV 2010).
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features.14 While U.S. federal agencies are busy grappling with the science
and scope of nanotechnology, research and development is swiftly moving
forward.15 As the gatekeeper to entrance of most medical and health care
products to the U.S. market, the FDA will play a large role in assessing the
applications of nanomedicine.
This Article will argue that the creation of the biosimilar pathway will
prove to be the straw that breaks the camel’s back unless the FDA develops
new dynamic models to properly assess and regulate nanomedical combination
products. This Article will examine the existing frameworks of FDA oversight
for medical and health care products, highlight nanotechnology (and
nanobiotechnology and nanomedicine) specifically as an area where products
are currently straddling traditional boundaries between FDA product
categories, discuss recent FDA initiatives and agency procedures regarding
nanotechnology, and will suggest an approach for the FDA to respond to
nanobiotechnology, which has enabled a set of products that drift
uncomfortably at the interface of drugs, medical devices, and biologics.
Part I will situate nanomedicine within the “nano” landscape, setting out its
scope and relationship to other technologies. Part II will examine the
traditional oversight frameworks of the FDA for drugs, biologics, and medical
devices; address the role of the FDA in protecting public health and safety in
development and use of those innovations in medicine and health care; and
identify key statutory provisions and regulations in the FDA realm. This part
will also identify core challenges and concerns regarding abbreviated routes to
market available for these types of products—the abbreviated new drug
approval process for drugs, the 510(k) process for medical devices, and the
newly created “biosimilar” and “interchangeable” route for biologics. It will
also set forth the framework for combination products, a streamlining process
tied directly to the drug, medical device, and biologic pathways. Part III will
examine the responses of the FDA to nanotechnology developments, including
the initiation of an agency-wide nanotechnology task force, internal policy
changes to gather nano-specific information from new drug applications, draft
guidance to industry on considerations for nanotechnology products, increased
requests for public comment and public meetings for input on specific aspects
of nanotechnology, and research partnerships. Part IV will then suggest
several approaches for the FDA to pursue in overseeing emerging products
blending drug, medical device, and biological aspects. These suggestions
include more effective use of the National Nanotechnology Initiative (“NNI”),

14. Jordan Paradise et al., Exploring Emerging Nanobiotechnology Drugs and Medical
Devices, 63 FOOD & DRUG L.J. 407, 417–20 (2008).
15. See, e.g., KK Jain, Advances in the Field of Nanooncology, BMC MEDICINE, Dec. 13,
2010, at 1, http://www.biomedcentral.com/content/pdf/1741-7015-8-83.pdf (discussing advances
in the use of nanotechnology in cancer treatment).
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the federal body tasked with aiding in nanotechnology research and
development, not only to promote and fund research but also to facilitate
collaboration on topics of oversight; reorganization of the FDA either through
congressional action or Commissioner action in order to properly classify,
assess, monitor, and regulate emerging nanomedical technologies and
products; and changes to FDA policy regarding data requirements and postmarket reporting from industry to address concerns about the scope of safety in
the context of nanomedical products. This will be followed by a brief
conclusion.
I. SITUATING NANOMEDICINE IN THE NANO SPECTRUM
A.

The Nanoscale and Nanotechnology

The nanoscale is the scale range below the microscale—traditionally
measured as under 100nm (or 10-9m, or one billionth of a meter).16 Scientists
and commentators have found interesting ways to illustrate this scale in a
manner comprehensible to the general public, including comparing the
nanoscale to the width of a human hair (where a strand of human hair is
approximately 40,000 nm in diameter)17 or the thickness of a sheet of paper
(where a sheet of paper is 100,000 nm thick).18 Simply put, nanoscale is all
about the size.
The term nanotechnology encompasses an array of technologies at the
nanoscale. The NNI defines “nanotechnology” as involving three inter-related
(and inseparable) aspects: (1) “[r]esearch and technology development at the
atomic, molecular or macromolecular levels, in the length scale of
approximately 1–100 nanometer” range; (2) “creat[ing] and us[ing] []
structures, devices and systems that have novel properties and functions
because of their small and/or intermediate sizes”; and (3) “ability to be
controlled or manipulated on the atomic scale.”19 Thus, a key feature of
nanotechnology is that while size matters, it is not everything. To be truly
nanotechnology, unique physical, chemical, and/or biological properties must
be present at the nanoscale that make the particle or material function in a
manner that can be harnessed and controlled to utilize those unique
properties.20 Thus, rather than merely connoting size, nanotechnology is all
16. NAT’L INST. OF STANDARDS & TECH., U.S. DEP’T OF COMMERCE, INTERNATIONAL
SYSTEM OF UNITS (SI) 29 (Barry N. Taylor & Ambler Thompson eds., 2008).
17. Nanotechnology Basics, NANOTECHNOLOGY NOW, http://www.nanotech-now.com/ba
sics.htm (last updated June 27, 2009).
18. Nat’l Nanotechnology Initiative, Size of the Nanoscale, NANO.GOV, http://www.nano.
gov/nanotech-101/what/nano-size (last visited Nov. 22, 2011).
19. U.S. ENVTL. PROT. AGENCY, NANOTECHNOLOGY: AN EPA RESEARCH PERSPECTIVE
FACTSHEET (2007), available at http://epa.gov/ncer/nano/factsheet/nanofactsheetjune07.pdf.
20. Id.
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about how the size contributes to unique and controllable properties and
functions.
Two other variations of the “nanotechnology” definition will factor into
discussions later in this Article. While all twenty-five agencies that make up
the NNI support the NNI definition, many have adapted it to deal with product
or process-specific issues facing that Agency. For example, the FDA’s Center
for Drug Evaluation and Research (“CDER”) hinges its scope of
nanotechnology to nanomaterials and nanoscale materials, which the Agency
defines as “any materials with at least one dimension smaller than 1,000 nm.”21
While the FDA acknowledges consultation of the existing NNI definition,22 the
CDER chose to designate the nanoscale as exceeding the traditionally
delineated 100 nm maximum by a tenfold difference, perhaps because the
Agency is observing drug products utilizing novel properties at numbers higher
than 100nm and prefers to be over-inclusive, rather than under-inclusive for
long-term tracking purposes. In fact, Abraxane, one of the first marketed
nanodrugs, has a 130nm mean particle size;23 other products may deviate from
the 100nm ceiling depending on the size of the actual drug product compared
to the total size of the particle containing the drug product and any
encapsulating material or adjuvant.24
The term nanotechnology itself and its use in scientific circles have
evolved. First entering into the technical and scientific lexicon in 1974, the
term “nano-technology” described the process of scaling down to an advanced
level of precision in the field of engineering (known as the “top-down
approach”)25; the term was further applied by K. Eric Drexler, a renowned
physicist, in 1986 to describe the scaling up of particles (known as the

21. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., MANUAL
5015.9: REPORTING FORMAT FOR NANOTECHNOLOGY-RELATED
INFORMATION IN CMC REVIEW 3 (2010) [hereinafter MAPP 5015.9 REPORTING FORMAT],
available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPolicies
Procedures/UCM214304.pdf.
22. Id. at 7.
Attachment B is titled “Search Terms for Populating the CDER
Nanotechnology Drug Product Database” and includes the National Nanotechnology Initiative
definition of “nanotechnology” as well as related definitions from professional organizations, the
FDA itself, scholarly scientific publications, and textbooks. Id.
23. See ABRAXIS BIOSCIENCE, INC., ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING
BRIEFING PACKAGE: ABRAXANE 5 (2006), available at http://www.fda.gov/ohrms/dockets/ac/06/
briefing/2006-4235B2-01-01AbraxisBioscience-background.pdf.
24. Draft Guidance for Industry: Considering Whether an FDA-Regulated Product Involves
the Application of Nanotechnology, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Regulatory
Information/Guidances/ucm257698.htm (last visited Jan. 22, 2011) [hereinafter Draft Guidance
for Industry].
25. Norio Taniguchi, On the Basic Concept of ‘Nano-Technology’, 2 PROC. OF THE INT’L
CONF. ON PRODUCTION ENGINEERING 18, 18 (1974).
OF POLICIES AND PROCEDURES
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“bottom-up approach”).26 Today, both top-down and bottom-up processes are
employed in order to arrive at the nanoscale and the unique properties that
emerge at that size; the choice of approaches varies by material and scientific
discipline.27 Unique nanoscale properties include electrical, where nanoscale
particles and materials can hold considerably more energy than conventional
sized materials because of their large surface area (e.g., carbon nanotubes
(“CNTs”) have an increased efficiency at conducting heat—carbon becomes a
superconductor at the nanoscale);28 optical, where linear and nonlinear optical
properties can be finely tailored by controlling the crystal dimensions and
surface chemistry (e.g., gold nanoparticles and quantum dots);29 chemical,
where nanoparticles can be used as catalysts30 and exhibit enhanced chemical
activity (e.g., silver at the nanoscale excels as an antimicrobial germ-killer and
nanoscale particles for drug delivery can cross into tumor vasculatures);31 and
mechanical, where nanomaterials exhibit increased hardness, fracture
toughness, scratch resistance, and fatigue strength (e.g., CNTs and C60
fullerenes).32
Depending on the particular area of development, nanotechnology may
include the use of nano-sized technology or processes to create specific
products or applications, the inclusion of nano-sized particles or materials, or
both. Products on the market that claim to be nanotechnology include
aerosols, pesticides and chemicals, air filtration systems, medical devices (such
as dental adhesives and diagnostic systems), robotics, pharmaceuticals,
cosmetics, and coatings and materials integrated into a wide variety of
consumer products (such as antibacterial coatings on wound dressings and
baby products, stain-resistant pants, high durability tennis rackets, and no-stick

26. K. ERIC DREXLER, ENGINES OF CREATION 3–20 (1986).
27. O. G. Schmidt et al., Nanotechnology—Bottom-up Meets Top-down, in 42 ADVANCES IN
SOLID STATE PHYSICS 231, 231–32 (Bernhard Kramer ed., 2002).
28. See, e.g., Ray H. Baughman et al., Carbon Nanotubes—The Route Toward Applications,
297 SCI. 787, 787, 791 (2002); Younan Xia et al., One-Dimensional Nanostructures: Synthesis,
Characterization, and Applications, 15 ADVANCED MATERIALS 353 (2003).
29. Xiaohu Gao et al., In Vivo Cancer Targeting and Imaging with Semiconductor Quantum
Dots, 22 NATURE BIOTECHNOLOGY 969 (2004).
30. See, e.g., Robert W. J. Scott et al., Synthesis, Characterization, and Applications of
Dendrimer-Encapsulated Nanoparticles, 109 J. PHYSICAL CHEMISTRY B 692, 696–702 (2005).
31. See, e.g., Döne Demirgöz et al., PR_b-Targeted PEGylated Liposomes for Prostate
Cancer Therapy, 24 LANGMUIR 13,518 (2008); Ashish Garg et al., Targeting Colon Cancer Cells
Using PEGylated Liposomes Modified with a Fibronectin-Mimetic Peptide, 366 INT’L J.
PHARMACEUTICS 201 (2009); Todd O. Pangburn et al., Peptide- and Aptamer-Functionalized
Nanovectors for Targeted Delivery of Therapeutics, J. BIOMECHANICAL ENGINEERING, July
2009, at 074005-1, 074005-2.
32. Erik T. Thostenson et al., Advances in the Science and Technology of Carbon Nanotubes
and Their Composites: A Review, 61 COMPOSITES SCI. AND TECH. 1899, 1899, 1905–07 (2001).
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cooking pans).33 It is often impossible to discern whether they are truly
nanotechnology products or whether the marketing claims are merely painting
the product in a space-age light.
As compared to the three-pronged NNI definition of nanotechnology, the
prefix “nano” is typically used to denote anything at the scale of under 100nm,
independent of whether there are novel characteristics or functions and an
ability to control. For example, materials and particles at the nanoscale are
called such terms as nanomaterials and nanoparticles, indicating merely that
they exist at the scale range under 100nm.34 The lesson to take away from this
is that not everything “nano” (think size) is “nanotechnology” (think size, plus
novel properties, plus ability to control).
Nanotechnology has garnered much attention from the federal government,
enjoying considerable funding and publicity which only promises to increase
as the technologies advance. In fact, the actual 2011 NNI budget provided
$1.85 billion in funding that supports nanoscale science and engineering
research and development spread across fifteen federal agencies.35 The
cumulative federal investment in nanotechnology through the NNI since 2001
is approximately $14 billion.36

33. The Woodrow Wilson Center’s Nanotechnology Consumer Products Inventory is a
useful resource that collects information on the “nano” marketing claims of consumer products
both in the United States and internationally. Woodrow Wilson International Center for Scholars,
Nanotechnology Consumer Products Inventory, NANOTECHPROJECT.ORG, http://www.nanotech
project.org/inventtories/consumer/ (last visited Nov. 30, 2011). The Inventory divides products
into multiple categories, including appliances, automotive, electronics and computers, food and
beverage, children’s goods, health and fitness, and home and garden. Id. While all of these
products share the common thread that the manufacturer or other source touts that they contain or
utilize “nanotechnology,” this is not necessarily the case.
34. See Nanotechnology Basics, supra note 17. The word “nano” is commonly related to a
Greek word meaning “dwarf.” Christian Joachim, To Be Nano or Not to Be Nano?, 4 NATURE
MATERIALS 107, 108 (2005).
35. Nat’l Nanotechnology Initiative, NNI Budget, NANO.GOV, http://www.nano.gov/aboutnni/what/funding (last visited Nov 30, 2011). The largest investments have been delivered to the
Department of Energy (energy technologies), National Science Foundation (science and
engineering generally), National Institutes of Health (biomedical research in the life and physical
sciences), the Department of Defense (defense and dual-use capabilities), and the National
Institute of Standards and Technology (measurement and fabrication tools, analytical
methodologies, and metrology). Id.
36. NNI Strategic Plan 2010; Request for Information, 75 Fed. Reg. 38,850, 38,851 (July 6,
2010). The total, including the NNI’s 2012 requests, would be $16.5 billion since 2001.
SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NAT’L SCI. & TECH. COUNCIL, THE
NATIONAL NANOTECHNOLOGY INITIATIVE: RESEARCH AND DEVELOPMENT LEADING TO A
REVOLUTION IN TECHNOLOGY AND INDUSTRY: SUPPLEMENT TO THE PRESIDENT’S 2012 BUDGET
7 (2011), available at http://nano.gov/NNI_2012_budget_supplement.pdf.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

2012]

B.

REASSESSING SAFETY FOR NANOTECHNOLOGY COMBINATION PRODUCTS

475

The Nano/Bio Interface and “Nanomedicine”

Nanobiotechnology is a narrower application of nanotechnology—“a field
that applies the nanoscale principles and techniques to understand and
transform biosystems (living or non-living) and which uses biological
principles and materials to create new devices and systems integrated from the
nanoscale.”37 This is essentially the application of nanotechnology to living
systems or the use of nanotechnology to create systems that mimic living
systems; this marriage makes inherent sense as biological cells and systems
often exist at the nanoscale naturally. For example, the largest amino acid
(tryptophan) measures 1.2nm,38 ribosomes measure approximately 2–4nm,39
DNA measures 2.5nm in width,40 and proteins typically measure between 1–
20nm.41
Given the natural relationship between the nanoscale and internal
properties and functioning of the human body, improvement of human health
and advancements in medicine are prime targets for nanotechnology.42 The
unique and far-ranging properties of nanostructures and nanotechnology have
facilitated breakthroughs in the pharmaceutical and medical device realms—a
confluence termed nanomedicine.43 The National Institutes of Health (“NIH”)
defines nanomedicine as a “highly specific medical intervention at the
molecular scale for curing disease or repairing damaged tissues, such as bone,
muscle, or nerve.”44 The FDA defines nanomedicine as “[t]he use of
nanoscale materials for medical applications.”45 Nanomedicine is a vastly
growing field in the United States, with projections that the market will reach
$53 billion in 2011.46 Massive amounts of federal funding are being directed
to nanomedicine research through the NNI—the NIH alone devoted $200
million to nanotechnology research in 2008.47 Many biological phenomena
37. Mihail C. Roco, Nanotechnology: Convergence with Modern Biology and Medicine, 14
CURRENT OPINION BIOTECHNOLOGY 337, 337 (2003).
38. KEWAL K. JAIN, THE HANDBOOK OF NANOMEDICINE 3 tbl.1.2 (2008).
39. Id.
40. Id.
41. Id.
42. See, e.g., Volker Wagner et al., The Emerging Nanomedicine Landscape, 24 NATURE
BIOTECHNOLOGY 1211, 1215, 1217 (2006).
43. Id. at 1212.
44. Nanomedicine: Overview, NAT’L INST. OF HEALTH COMMON FUND, http://common
fund.nih.gov/nanomedicine/overview.aspx (last updated Jan. 1, 2011).
45. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 3.
46. Raj Bawa & Summer Johnson, The Ethical Dimensions of Nanomedicine, 91 MED.
CLINICS N. AM. 881, 882 (2007) (citing Freedonia Grp., NANOTECHNOLOGY IN HEALTHCARE
(2007)).
47. NANOTECHNOLOGY TASK FORCE, NAT’L INSTS. OF HEALTH, 2008 STATEMENT OF
PURPOSE (2008), available at http://www.nibib.nih.gov/nibib/file/Research/Nanotechnology/
NIH_Nanotechnology_Task_Force_Plan_FINAL_Jan09.pdf.
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naturally occur at the nanoscale; however, nanomedicine refers to materials or
particles fabricated at this scale to take advantage of manifest properties (e.g.,
optical, chemical, and mechanical).48 Products at the nanoscale are emerging
that utilize and integrate nanoscale properties, have the ability to mimic
biological systems, and will, in time, be able to functionally evolve in response
to bodily feedback.
Research at the nanoscale illustrates that as particle size decreases, and
surface area increases, the biological activity of particles increases.49 The
resulting unique physical properties at the nanoscale are extremely promising
for medical applications in that they may solve some of the most difficult
barriers for effective therapeutics and diagnostics.50 In terms of in vitro and in
vivo imaging, nanoscale properties involving optical absorbance, fluorescence,
and electrical and magnetic conductivity are key to locate and visualize
internal functioning;51 for drug delivery and formulation of drugs, nanoscale
properties involving pharmacokinetics, biodistribution, and cell permeability
will assist in getting the drug load to the exact location, and faster;52 and for
implants, bone and dental restoratives, and coatings for wound care and
various other applications, the size and shape, surface modification, and direct
interaction with tissues will increase efficacy.53 The interface of nanomedicine
and nanobiotechnology has introduced widespread research activity in the
areas of biomolecule and biomimetic devices, biosensors, molecular motors,
biomolecular fabrics, engineered enzymes and proteins, and drug discovery
and delivery.54
As will be discussed in Part III, little to nothing is yet known about the
health, safety, and environmental impacts of nanomaterials and nanoparticles.
Scientists and regulators alike are struggling to quantify and characterize these
materials in an effort to create appropriate toxicological testing and assessment
tools.55 Specific to human safety and public health, there are broad questions
48. Nanomedicine: Overview, supra note 44.
49. Andre Nel et al., Toxic Potential of Materials at the Nanolevel, 311 SCI. 622, 622
(2006); see also Andre E. Nel et al., Understanding Biophysicochemical Interactions at the NanoBio Interface, 8 NATURE MATERIALS 543, 554 (2009) (discussing particle size, surface area, and
bioreactivity in the context of pulmonary inflammation).
50. Nagender Reddy Panyala et al., Gold and Nano-Gold in Medicine: Overview, Toxicology
and Perspectives, 7 J. APPLIED BIOMEDICINE 75, 75 (2009).
51. Id. at 76–77, 84.
52. Pawan Malhotra & Aneeta Singh, Nano Medicine—A Futuristic Approach, 12 JK SCI. 3,
3 (2010), http://www.jkscience.org/current/Nano%20Medicine-%20A%20Futuristic%20Ap
proach.pdf.
53. See id. at 4 (noting that nanomachines that enter cells are able to more effectively make
“modifications of faulty [cell] structure”).
54. Alan L. Porter et al., Refining Search Terms for Nanotechnology, 10 J. NANOPARTICLE
RES. 715, 718 fig.1 (2008).
55. See infra Part II.
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about the toxicity of nanoparticles in humans and whether animal research
findings are an adequate measure to draw conclusions for risks of human
exposure,56 the effect of various exposure routes and routes of administration,
possible unintended effects on non-target areas given the ability of
nanoparticles to cross the blood-brain barrier, possible long-term effects of
nanoparticles introduced to the human body,57 and potential interaction of
various nanoparticles and nanomaterials within the human body.58 Struggles to
develop mechanisms to identify, quantify, and assess the health and
environmental impacts of nanotechnology are not confined to the United
States; this is a global challenge.59 While developing and developed countries
alike are channeling funding into nanotechnology research and development,
resulting in a vast spectrum of consumer products entering the market, the
scientific and regulatory questions abound. The U.S. government, through the
NNI, is currently funding targeted research studies within core research
institutes and agencies on a number of environmental and public health and
safety implications.60 It is also, however, spending over ninety-three percent
of its current budget on development and support of nanotechnology
applications.61
As nanotechnology advances, particularly in the realm of medicine and
human health, ample attention to scientific developments in characterizations
and assessment, adverse event reporting specific to nanocharacteristics, and
post-market surveillance are necessary to investigate and respond to the effects
of these products on the public. Several key federal agencies, including the
FDA, the Environmental Protection Agency (“EPA”), and the Occupational
Safety and Health Administration, are situated to play a large part in
generating, tracking, and disseminating this information. Part II provides an

56. See David B. Resnik & Sally S. Tinkle, Ethical Issues in Clinical Trials Involving
Nanomedicine, 28 CONTEMP. CLINICAL TRIALS 433, 434–37 (2007) (noting limitations of animal
experimentation in discerning long-term effects and differing reactivity between animals and
humans).
57. Bawa & Johnson, supra note 46, at 885.
58. Christian Lenk & Nikola Biller-Andorno, Nanomedicine—Emerging or Re-Emerging
Ethical Issues? A Discussion of Four Ethical Themes, 10 MED. HEALTH CARE & PHIL. 173, 176
(2007).
59. See infra Part III.A.
60. See, e.g., SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NAT’L SCI. & TECH.
COUNCIL, NATIONAL NANOTECHNOLOGY INITIATIVE STRATEGIC PLAN 29–30 (2011), available
at http://www.nano.gov/nnistrategicplan211.pdf.
61. This is based on the NNI’s 2011 budget of a total of $1.76 billion, with $117 million for
environmental, health, and safety research. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH.,
NAT’L SCI. & TECH. COUNCIL, THE NATIONAL NANOTECHNOLOGY INITIATIVE: RESEARCH AND
DEVELOPMENT LEADING TO A REVOLUTION IN TECHNOLOGY AND INDUSTRY, SUPPLEMENT TO
THE PRESIDENT’S 2011 BUDGET 11 (2010), available at http://nano.gov/sites/default/files/pub_re
source/nni_2011_budget_supplement.pdf.
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overview of the FDA’s oversight of drugs, medical devices, and biologics,
highlighting the abbreviated approval pathways to market and in particular the
biosimilar pathway introduced in the ACA, and the mechanisms of overseeing
products that combine aspects of these three product areas.
II. TRADITIONAL FOOD AND DRUG ADMINISTRATION OVERSIGHT
FRAMEWORKS FOR MEDICAL AND HEALTH CARE PRODUCTS
One of eleven agencies within the Department of Health and Human
Services (“DHHS”), the FDA is tasked with enforcing a broad range of federal
statutes with products accounting for a quarter of all consumer spending in the
United States, including eighty percent of the national food supply and all
human drugs, medical devices, cosmetics, vaccines, tissues for
transplantations, and radiation-emitting products.62 In addition to overseeing
products, the FDA is also “responsible for advancing the public health by
helping to speed innovations that make medicines more effective, safer, and
more affordable and by helping the public get the accurate, science-based
information they need to use medicines and foods to . . . improve their
health.”63 Recent legislation also provides both increased authority over
tobacco products64 and a new approval pathway for follow-on biologics65 that
further enlarges the FDA docket.
The FDCA delineates three product categories applicable to nanomedicine:
drugs, medical devices, and biologics.66 These are the three most heavily
regulated consumer products throughout the pre- and post-marketing phases

62. Regulatory Information: Legislation, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
RegulatoryInformation/Legislation/default.htm (last updated May 4, 2011); Press Release, U.S.
Food & Drug Admin., The Food and Drug Administration Celebrates 100 Years of Service to the
Nation (Jan. 4, 2006), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce
ments/2006/ucm108572.htm.
63. What We Do, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/WhatWeDo/
default.htm (last visited Jan. 22, 2012).
64. Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 Stat.
1776, 1776–1852 (2009) (codified in scattered sections of the U.S. Code).
65. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7002, 124 Stat. 119,
804–821 (2010) (codified at 42 U.S.C. § 262 (Supp. IV 2010) & 21 U.S.C. § 355(a) (Supp. IV
2010)). The biosimilars provisions are found in Title VII: Biologics Price Competition and
Innovation. The new follow-on biologics provisions create statutory mechanisms to provide for
approval of a biological product that is “biosimilar” and/or “interchangeable” with a biologic
reference product already on the market. This status is to be based on whether a follow-on
product is “highly similar” to the reference product. Id. A biologic is defined as “a virus,
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic
product, or analogous product, or arsphenamine or derivative of arsphenamine (or any other
trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease
or condition of human beings.” 42 U.S.C. § 262(i) (2006).
66. See infra Part II.A–C.
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with substantial data requirements and a spectrum of compliance and
enforcement mechanisms in the FDA’s arsenal. However, the extent of
regulation varies according to a multitude of factors, including whether a drug
is a new drug or a generic drug, whether a medical device must go through the
premarket approval process or is substantially equivalent to a device already on
the market,67 and, following the 2010 health care legislation, whether a
biologic product is biosimilar and thus able to progress through a streamlined
(and yet to be developed) approval process.68 A broad overview of the
pathway to market for drugs, medical devices, and biologics is below.
A.

Human Drugs

Oversight of both human drugs and medical devices is set out in the
FDCA.69 The new drug application (“NDA”) process involves the most
rigorous review of any FDA-regulated product and is overseen by the CDER.70
It can take upwards of sixteen years and cost over a billion dollars to bring a
new drug to market.71 The touchstone measures of this process are ultimately
safety and efficacy but oversight by the FDA spans identification, synthesis,
and purification of an active pharmacological ingredient; pre-clinical and
animal testing; clinical trials; manufacturing processes; review of the product
for final approval; and post-market performance.72 New human drugs73 must

67. An extended discussion of the FDA drug and medical device review, approval, and
clearance processes are outside the scope of this article. They are addressed extensively
elsewhere in the literature.
68. 42 U.S.C. § 262(i)(2)–(3) (Supp. IV 2010).
69. Pub. L. No. 75-717, 52 Stat. 1040 (codified as amended in scattered sections of 21
U.S.C.).
70. About the Center for Drug Evaluation and Research, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/
default.htm (last visited Jan. 22, 2012).
71. Chris L. Waller et al., Strategies to Support Drug Discovery Through Integration of
Systems and Data, 12 DRUG DISCOVERY TODAY 634, 634 (2007).
72. 21 U.S.C. § 355 (2006).
73. A drug is defined as:
(A) articles recognized in the official United States Pharmacopeia . . . ; and (B) articles
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
man or other animals; and (C) articles (other than food) intended to affect the structure or
any function of the body of man or other animals; and (D) articles intended for use as a
component of any articles specified in clause (A), (B), or (C).
Id. § 321(g)(1). A new drug is defined as:
(1) Any drug (except a new animal drug or an animal feed bearing or containing a new
animal drug) the composition of which is such that such drug is not generally recognized,
among experts qualified by scientific training and experience to evaluate the safety and
effectiveness of drugs, as safe and effective for use under the conditions prescribed,
recommended, or suggested in the labeling.
Id. § 321(p)(1).
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satisfy safety, efficacy, and manufacturing standards, among other substantive
requirements.74 Applicants must progress through key stages in the approval
process including an investigational new drug application (“IND”) based on
animal studies and three core stages of clinical trials, culminating in an NDA.75
The FDA also maintains significant post-market authority over approved drug
products as a result of 2007 amendments.76
Under the NDA umbrella, there are three routes for drugs to enter the
market faster where they are intended to treat serious or life-threatening
diseases: priority review, fast track, and accelerated approval.77 These have
been established either by agency policy, regulation, or statute.78 Each route is
distinct, but they share the underlying goal of speeding up the availability of
the drug based on its treatment promise.79 Priority review is a designation
given to new drug applications by FDA reviewers in order to speed up the time
of review by a few months for drugs that appear to offer major advances in
treatment or will provide treatment where there is currently no adequate
therapy.80

74. Id. § 355.
75. Details of the NDA process are detailed elsewhere. Following FDA approval of an
Investigational New Drug (“IND”) application, clinical trials involve three key phases. Phase I
studies are conducted on healthy subjects for basic metabolism, pharmacology and initial safety
and dosage measures. Phase II studies are larger scale (several hundred people) and collect initial
measures of effectiveness and continues safety, toxicology, and dosage measures. The sponsor
meets with the FDA at the end of Phase II in order to continue into Phase III, which enroll up to
several thousand subjects for large-scale safety and efficacy measures, and specifically to identify
rare adverse events in a larger population. The FDA’s Drug Review Process: Ensuring Drugs Are
Safe and Effective, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/ResourcesForYou/
Consumers/ucm143534.htm (last visited Jan. 22, 2012).
76. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat.
823 (codified as amended in scattered sections of 21 U.S.C.). The Food and Drug Administration
Amendments Act (“FDAAA”), among other provisions, expanded the scope of clinical trial
registration and post-market surveillance in response to growing concerns about public
availability of trial information and is viewed as a strong step forward in efforts to increase
transparency. Many question the utility of the information in the face of limited public
understanding and ability to interpret results and urge more efforts to promote public
understanding of clinical trial information that is put into the public domain. See, e.g., Deborah
A. Zarin & Tony Tse, Moving Toward Transparency of Clinical Trials, 319 SCI. 1340, 1342
(2008).
77. Fast Track, Accelerated Approval and Priority Review, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnew
therapies/ucm128291.htm (last visited Jan. 22, 2012) [hereinafter Fast Track].
78. Id.
79. Id.
80. This designation and process is established in agency policy and effectively sets the goal
for time of review at six months rather than ten months for standard review. Id. For examples of
agency policy regarding expedited drug approval, see CTR. FOR DRUG EVALUATION AND
RESEARCH, U.S. FOOD & DRUG ADMIN., MANUAL OF POLICIES AND PROCEDURES 6020.3:
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Fast Track is defined by the FDA as “a process designed to facilitate the
development, and expedite the review of drugs to treat serious diseases and fill
an unmet medical need.”81 The FDA considers factors such as the impact on
day-to-day functions and survival or the likelihood that, if left untreated, the
disease will become more serious in order to determine whether it is serious or
life-threatening.82 Where no treatments exist, this is clearly an “unmet need”;
where therapies do currently exist, the drug must show that it performs some
advantage over that existing product.83 This approval process typically
requires post-approval studies and the progress of these studies, as well as the
plan for completion or termination and any reasons for delay, must be
described in the annual report to the FDA.84 The FDA may also waive the
IND application requirement and may accept a continuous application during
the Fast Track process, where portions of the NDA may be submitted before a
full NDA is prepared, allowing frequent feedback and interactions throughout
the development process.85
Accelerated review allows the earlier approval of drugs that are intended to
treat serious diseases or life-threatening diseases and fill an unmet medical
need based on a surrogate endpoint rather than a traditional clinical trial
outcome measure.86 The FDA may also impose post-market studies as part of
the accelerated approval, tasking the drug sponsor to “study the drug further, to
verify and describe its clinical benefit, where there is uncertainty as to the
relation of the surrogate endpoint to clinical benefit, or of the observed clinical
benefit to ultimate outcome.”87 The regulations provide circumstances under
which the FDA may withdraw the approved drug from the market, subject to

REVIEW OF CLASSIFICATION POLICY: PRIORITY (P) AND STANDARD (S) (2007); SOPP 8405:
Complete Review and Issuance of Action Letters, U.S. FOOD & DRUG ADMIN., http://www.fda.
gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ProceduresSOPPs/
ucm073481.htm (last visited Jan. 22, 2012).
81. Fast Track, supra note 77. This process was established by statute. 21 U.S.C. § 356(a)
(2006).
82. Fast Track, supra note 77.
83. Id.
84. 21 U.S.C. § 356(b) (outlining the requirements for the reports of post-marketing studies).
This provision requires that the company’s annual report identify each Phase IV commitment
(post-market studies) for the approved product, describe the progress being made, and indicate the
plan for completion or termination. Id.
85. See Fast Track, supra note 77.
86. This process was established by regulation. 21 C.F.R. §§ 314.500–560, 601.40–601.46
(2010). Surrogate endpoints are physiological assessments recognized as validated indicators of
clinical benefit (i.e., a biomarker). Id. § 314.510. Examples include reduced blood pressure for
anti-hypertensives, reduced fractures for osteoporosis, and reduced cholesterol levels for lipidaltering drugs.
87. Id. § 314.510.
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notice and a hearing. These include failure to verify clinical benefit and failure
to perform a required post-market study with due diligence.88
Increasing concern about the failure to assure that industry fulfill postapproval commitments led to the Food and Drug Administration Amendments
Act of 2007 (“FDAAA”).89 Pre-2007, the FDA relied on two statutory
provisions broadly dealing with maintenance of records and reports as the basis
for requests for post-approval nonclinical or clinical studies (aside from those
required under the accelerated approval regulations).90 With enactment of
FDAAA, the authority of the FDA to require post-approval studies has been
explicitly provided; the FDA can now rely on new provisions to require further
studies for safety and efficacy, along with increased authority to review these
commitments.91 Risk evaluation and mitigation strategies (“REMS”) come in
many forms: they can require a Medication Guide for patients, prescription
physician information, implementation plans, communications to health care
providers and pharmacies, and various limitations on labeling, promotion, and
prescribing to assure safe use.92 These amendments provide significant
enforcement mechanisms for violations, which are deemed to be misbranding
and carry additional civil money penalties for violations.93 The FDAAA also
provides additional requirements for the industry regarding the entry of clinical
trial information into existing clinical online databases and creation of new
online reporting resources for adverse events as a means to bolster
transparency to the public.94
However, problems with industry adherence to post-market requirements
linger. In September 2009, the U.S. Government Accountability Office
(“GAO”) issued a report addressing perceived problems with the FDA’s
accelerated approval program.95 The report details that while the FDA
approved ninety drug applications based on surrogate endpoints between 1992
and November 2008, only two-thirds of the required post-market studies have
been fulfilled and deemed “closed” by the FDA.96 Pointing out weakness in
monitoring and enforcement, the GAO urged the FDA to clarify conditions for
withdrawal if sponsors fail to complete the required studies or if the studies fail

88. Id. § 314.530.
89. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat.
823 (codified as amended in scattered sections of 21 U.S.C.).
90. See 21 U.S.C. §§ 355(e), (k) (2006).
91. See 21 U.S.C. §§ 355(o)–(p), 355-1 (Supp. IV 2010).
92. Id. § 355-1.
93. Id. § 352(y)–(z); Id. § 333(f)(4).
94. Id. § 355(k).
95. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-090-866, NEW DRUG APPROVAL: FDA
NEEDS TO ENHANCE ITS OVERSIGHT OF DRUGS APPROVED ON THE BASIS OF SURROGATE
ENDPOINTS (2009) [hereinafter FDA NEEDS TO ENHANCE ITS OVERSIGHT].
96. Id. at 14.
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to demonstrate the drug’s clinical effectiveness.97 Likely as a result of this
report critical of the FDA’s handling of these products, the FDA recently
asserted this withdrawal authority for the first time, notifying Shire
Pharmaceuticals and generic manufacturers of the Agency’s proposal to
withdraw ProAmatine (and the generic midodrine) from the market based on a
lack of required post-marketing data confirming the clinical benefit of the
drug.98 The FDA has since opened a public docket on the matter.99
A drug sponsor may also apply for changes to a drug approval utilizing a
supplemental NDA (“sNDA”)100 where an approved application exists that
underwent a full premarket approval process and the sponsor wishes to make
changes to that marketed drug.101 These are termed “prior approval”
supplements and FDA approval is required before changes are implemented.102
Only major changes require a sNDA: changes to the drug or the manufacturing
process, facilities, or equipment that have “a substantial potential to have an
adverse effect on the identity, strength, quality, purity, or potency of the drug
product as these factors may relate to the safety or effectiveness of the drug
product.”103 These are typically changes to the active ingredient or active
product, including major labeling changes such as a new indication or new
dosing and major manufacturing changes such as formulation or synthesis
changes.104
The generic drug approval process, termed the abbreviated new drug
application (“ANDA”), was implemented in 1984 with the Hatch-Waxman
Act.105 The ANDA process combines patent term extension and data
exclusivity provisions with authorization for the FDA to approve generic
versions of already-approved pioneer drugs.106 These provisions were
applicable only to conventional small molecule drugs and did not include

97. Id. at 36.
98. Midodrine Update, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/
ucm225444.htm (last visited Jan. 22, 2012).
99. Id.; see also Trials to Verify and Describe Clinical Benefit of Miodrine Hydrochloride;
Establishment of Public Docket, 76 Fed. Reg. 1620 (Jan. 11, 2011).
100. 21 U.S.C. § 356a(c)(1) (2006).
101. 21 C.F.R. § 314.70 (2010).
102. CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., GUIDANCE
FOR INDUSTRY: CHANGES TO AN APPROVED NDA OR ANDA 3 (2004), available at
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM077097.pdf [hereinafter CHANGES TO AN APPROVED NDA OR ANDA].
103. 21 C.F.R. § 314.70(b)(1) (2010).
104. CHANGES TO AN APPROVED NDA OR ANDA, supra note 102, at 12–13.
105. The Drug Price Competition and Patent Term Restoration Act of 1984 (also known as
the Hatch-Waxman Act) established the abbreviated new drug application process at 21 U.S.C. §
355(j) (2006). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98417, sec. 101, 98 Stat. 1585, 1585–92 (codified at 21 U.S.C. § 355(j) (2006)).
106. 21 U.S.C. § 355(j).
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biologics, which are regulated under the rubric of the Public Health Services
Act.107 An ANDA does not generally require preclinical and clinical data to
establish safety and efficacy but must demonstrate that the product is
“bioequivalent” and performs in the same manner as the pioneer drug in terms
of active ingredient, dosage and route of administration, and strength and
conditions of use.108 A showing of bioequivalence requires “the absence of a
significant difference in the rate and extent to which the active ingredient or
active moiety in pharmaceutical equivalents or pharmaceutical alternatives
becomes available at the site of drug action when administered at the same
molar dose under similar conditions in an appropriately designed study.”109
The FDA may approve an ANDA for a generic version of a pioneer drug after
all relevant patents have expired for the pioneer drug and all relevant periods
of market exclusivity for the pioneer drug have also expired.110 The Orange
Book is the key resource to guide the ANDA applicant and includes patent
listings and information on generic drug approvals and the corresponding
pioneer drug.111 State substitution laws allow pharmacists to dispense the
generic (i.e., therapeutic equivalent) drug when a physician prescribes the
pioneer, except if explicitly directed otherwise by physician.112
Nanodrugs are currently being evaluated by the FDA via the NDA process.
However, a number of them have benefited from accelerated approval because
of their application in treatments for serious or life-threatening illnesses.113 The
GAO report’s Appendix I lists the drugs approved under the accelerated
approval process during the 1992 to November 2008 time period, including the
107. Jordan Paradise, The Devil is in the Details: Health-Care Reform, Biosimilars, and
Implementation Challenges for the Food and Drug Administration, 51 JURIMETRICS J. 279, 282
(2011).
108. 21 U.S.C. § 355(j)(2)(A)(ii)–(iii).
109. 21 C.F.R. § 320.1(e) (2010). Bioavailability is defined as “the rate and extent to which
the active ingredient or active moiety is absorbed from a drug product and becomes available at
the site of [drug] action.” Id. § 320.1(a). The drug product is defined as the “finished dosage
form . . . that contains the active drug ingredient, generally, but not necessarily, in association
with inactive ingredients.” Id. § 320.1(b). Pharmaceutical equivalents are defined as drug
products “that contain identical amounts of the identical active drug ingredient.” Id. § 320.1(c).
And pharmaceutical alternatives are defined as “drug products that contain the identical
therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form.” Id.
§ 320.1(d).
110. 21 U.S.C. § 355(j)(5)(A)–(E).
111. CTR. FOR DRUG EVALUATION & RESEARCH, U.S. FOOD & DRUG ADMIN., APPROVED
DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (THE ORANGE BOOK) (31st
ed. 2011), available at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/
UCM071436.pdf. The Orange Book lists patent and exclusivity information for pioneer and
generic drugs. The searchable electronic version is available at http://www.accessdata.fda.gov/
scripts/cder/ob/default.cfm.
112. Jesse C. Vivian, Generic-Substitution Laws, U.S. PHARMACIST, June 2008, at 30, 32–33.
113. See infra Figure 1.
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drugs Doxil (approved both for treatment of Kaposi’s sarcoma in specific
patients with Acquired Immunodeficiency Syndrome and for treatment of
metastatic carcinoma of the ovary in specific patients) and DepoCyt (approved
Both drugs utilize
for treatment of lymphmatous meningitis).114
nanotechnology.115 As companies with existing NDAs for nanotechnologybased drugs pursue additional indications, dosages, and patient populations,
many will utilize the sNDA route to achieve this. For example, Abraxis
Biosciences reported in early 2010 that it was near completion of Phase 3
clinical trials for a second indication of Abraxane (active ingredient paclitaxel)
originally approved in 2005, which the company projected would be the
subject of an sNDA sometime in 2011.116 Ortho Biotech has also utilized the
sNDA process for several subsequent new or modified indications of Doxil
(active ingredient doxorubicin hydrochloride), as well as labeling changes.117
B.

Medical Devices

Medical devices118 are subject to a tiered classification system based on
perceived level of risk. Most medical devices considered low and medium risk
can be marketed with merely a premarket notification to the FDA if
“substantially equivalent” to an already marketed device or may be exempt
from premarket notification altogether; higher-risk Class II or Class III devices
that are not substantially equivalent must go through a pre-market process

114. Both drugs were approved using response rate as the surrogate endpoint. See FDA
NEEDS TO ENHANCE ITS OVERSIGHT, supra note 95, at 42, 44 tbl.5.
115. Paradise et al., supra note 14, at 411–12; see infra Figure 1.
116. Press Release, Abraxis Bioscience, Abraxane Meets Primary Endpoint in Phase 3 Trial
for Advanced Non-Small Cell Lung Cancer, (Mar. 17, 2010), available at http://www.nanotechnow.com/news.cgi?story_id=37282 (last visited Aug. 8, 2011). Celgene acquired Abraxis
Biosciences in June 2010. Andrew Pollack, Prominent Drug Chief to Sell Abraxis BioScience to
Celgene for $2.9 Billion, N.Y. TIMES, July 1, 2010, at B3.
117. Doxil Label and Approval History, U.S. FOOD & DRUG ADMIN., http://www.access
data.fda.gov/scripts/cder/drugsatfda/index.cfm (search the drug name “Doxil”; then follow “Label
Information” hyperlink) (last visited Jan. 22, 2012).
118. A medical device:
means an instrument, apparatus, any component, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article, including any component part,
or accessory which is –
(1) recognized for use in the official National Formulary, or . . . ,
(2) intended for use in the diagnosis of disease or other conditions, or in the cure,
mitigation, treatment, or prevention of disease, in man or other animals, or
(3) intended to affect the structure or any function of the body of man or other animals,
and
which does not achieve its primary intended purposes through chemical action within or
on the body of man or other animals and which is not dependent upon being metabolized
for the achievement of its primary intended purposes.
21 U.S.C. § 321(h) (2006).
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demonstrating safety and efficacy as set forth in regulations.119 The Center for
Devices and Radiological Health (“CDRH”) oversees medical devices.120
Class III is the highest risk classification for medical devices, requiring a
pre-market approval (“PMA”) filing prior to marketing in the United States
unless it is a product amenable to the 510(k) clearance process based on
classification listings and “substantial equivalence,” described below.121 Class
III PMA devices are those that are life-sustaining and life-supporting.122
Similar to an NDA for a new drug, the PMA must list uses and indications of
the specific product, warning and contraindications, product labeling, results of
clinical trials gathered following approval of an investigational device
exemption (comparable to an IND for a new drug), and information regarding
manufacturing processes.123 Examples of high-risk Class III products subject
to the PMA process include heart valves, implantable cardioverter
defibrillators, and pacemakers.124 Clinical studies for a Class III medical
device can take four to five years and cost fifteen to twenty million dollars.125
Premarket notification is required for most Class II and III devices, which
is termed a 510(k) clearance in reference to the FDCA section that establishes
the process.126 These devices pose an increased, moderate level of risk.127
This process does not mandate a drug-like clinical trial and PMA process as is
required for Class III highest risk devices. Rather, it requires a submission that

119. 21 U.S.C. § 360(c).
120. About the Center for Devices and Radiological Health, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/de
fault.htm (last visited Jan. 22, 2012).
121. The established 510(k) classifications for device manufacturers are listed in 21 C.F.R. §§
862–880 (2010). If a new device has the same intended use and meets the general description of
the device in the classification, then the new device will fall under that regulation scheme. If the
device is not currently listed, it will be considered a Class III device and subject to premarket
approval requirements until the FDA determines otherwise.
122. Edward C. Wilson, Jr. & Laurie A. Clarke, The Medical Device Approval Process, in A
PRACTICAL GUIDE TO FOOD AND DRUG LAW AND REGULATION 127, 129 (Kenneth R. Piña &
Wayne L. Pines, eds., 2d ed. 2002). These products must typically first complete clinical testing
under an investigational device exemption (“IDE”), which is similar in content and requirements
to the drug IND but generally involves fewer participants and less extensive clinical trials. Jordan
Paradise et al., Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the
FDA and Implications for Nanobiotechnology, 37 J.L. MED. & ETHICS 598, 602 (2009).
123. 21 U.S.C. § 360e(c) (2006).
124. See Alan M. Garber, Modernizing Device Regulation, 362 NEW ENG. J. MED. 1161
(2010).
125. Andrew S. Baluch, Angstrom Medica: Securing FDA Approval and Commercializing a
Nanomedical Device, 2 NANOTECHNOLOGY L. & BUS. 168, 172 (2005).
126. 21 U.S.C. § 360(k) is also expressed as Food, Drug, and Cosmetic Act § 510(k). Some
Class II devices are exempt as classified in the Federal Register. See 21 C.F.R. §§ 862–892
(2010).
127. 21 U.S.C. § 360(k).
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a device is “substantially equivalent” to a device already on the market and
provides for special controls,128 which include performance standards, postmarket surveillance, patient registries, development of guidelines,
recommendations and other actions deemed appropriate by the FDA to
“provide reasonable assurance of safety and effectiveness.”129 Substantial
equivalence is defined as either: (1) having the same intended use and the same
technological characteristics of an existing device; or (2) having the same
intended use and different technological characteristics but the information
submitted to the FDA does not raise new questions of safety and efficacy and
demonstrates that the device is at least as safe as the legally manufactured
device.130 Review times are approximately three months for a 510(k)
submission and eight and a half months for a Class III PMA device.131
Reportedly, of the first six nano-medical devices to enter the market, none
were approved through the PMA approval process but instead the 510(k)
process based on substantial equivalence to an existing device.132 The FDA
website reveals that the overwhelming majority of medical devices utilizing
the term “nano” (and appropriately described as operating or containing
materials at the nanoscale) have been cleared through the 510(k) process.133
Finally, Class I devices are the lowest level of risk, subject typically to
general controls which consist of facility registration and product listing with
the FDA, record maintenance and filing of marketing reports, adherence to
good manufacturing procedures (“GMPs”) and quality system registrations
(“QSRs”), and any distribution and use limitations imposed by the FDA.134
All devices (Class I–III) are subject to these general controls; additional
controls are added as the perceived level of risk increases. All Class I devices
undergo either the 510(k) process or are exempt from premarket notification
entirely via FDA policy or regulation.135
A recent IOM report revealed that a staggering ninety-nine percent of
medical devices enter the market either through the 510(k) process or are

128. Id. § 360c(a)(1)(B).
129. Id.
130. Id. § 360c(i)(1)(A).
131. Elizabeth Mansfield et al., Food and Drug Administration Regulation of in Vitro
Diagnostic Devices, 7 J. MOLECULAR DIAGNOSTICS 2, 3 (2005).
132. Gary E. Marchant et al., International Harmonization of Regulation of Nanomedicine, 3
STUD. ON ETHICS L. & TECH art. 6, at 3–4 (2009), http://www.bepress.com.ezp.slu.edu/cgi/view
content.cgi?article=1120&context=selt.
133. The FDA website has a searchable link for 510(k) and PMA medical devices, arranged
by year. For the 510(k) search, visit http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/
pmn.cfm (last updated Jan. 5, 2012). For the PMA search, visit http://www.accessdata.fda.gov/
scripts/cdrh/cfdocs/cfPMA/pma.cfm (last updated Jan. 5, 2012). See also infra Figure 2.
134. 21 U.S.C. § 360c(a)(1)(A) (2006).
135. PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 992 (3d ed. 2007).
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exempt from any premarket review each year.136 The Director of the CDRH
indicates that this amounts to approximately 3,000 products passing through
the 510(k) process each year.137 In response to ongoing criticism and Congress
tasking the IOM with a critique of the 510(k) system,138 the CDRH has
conducted internal investigations of the 510(k) process. The CDRH released
two preliminary reports in August 2010 assessing: (1) the existing oversight
frameworks for 510(k) medical devices;139 and (2) the CDRH’s utilization of
scientific information in decision-making within the Agency.140 The 510(k)
report addresses long-standing concerns regarding the utilization of substantial
equivalence measures rather than requiring premarket approval processes for
assuring safety and efficacy.141 One finding highlighted within the report was
the inconsistent interpretation of terms such as “substantial equivalence,”
“intended use,” and “different technological characteristics” and the
relationship of these terms to the predicate device.142 This is especially
relevant with respect to nanotechnology, as most medical devices utilizing
nanotechnology have been cleared via the 510(k) route.143 Undoubtedly, these
medical devices exhibit new features, properties, and characteristics due to the
nanoscale, raising questions about whether the FDA has appropriately allowed
them clearance under the 510(k) process.
The second CDRH report acknowledges the needs of the FDA in the face
of new scientific information: the need for high-quality and up-to-date
information on new science; the need for analytical and technical expertise to
assess new science; and the need for operational and organizational
136. INST. OF MED., supra note 3, at 4; see also Protecting Patients from Defective Medical
Devices: Hearing on S. 540 Before the S. Comm. on Health, Educ., Labor and Pensions, 111th
Cong. 30 (2009) (testimony of Peter Barton Hutt, Senior Counsel, Covington & Burling LLP).
137. Letter from Jeffrey Shuren, Dir., U.S. Food & Drug Admin. Ctr. for Devices &
Radiological Health, to the American Public, available at http://www.fda.gov/downloads/About
FDA/CentersOffices/CDRH/CDRHReports/UCM239451.pdf.
138. Activity Description, Public Health Effectiveness of the FDA 510(k) Clearance Process,
INST. OF MED., http://www.iom.edu/Activities/PublicHealth/510KProcess.aspx (last updated
Aug. 1, 2011).
139. CTR. FOR DEVICES AND RADIOLOGICAL HEALTH, U.S. Food & Drug Admin., 1 CDRH
PRELIMINARY INTERNAL EVALUATIONS: 510(K) WORKING GROUP PRELIMINARY REPORT AND
RECOMMENDATIONS (2010) [hereinafter 510(K) REPORT].
140. CTR. FOR DEVICES AND RADIOLOGICAL HEALTH, U.S. Food & Drug Admin., 2 CDRH
PRELIMINARY INTERNAL EVALUATIONS: TASK FORCE ON THE UTILIZATION OF SCIENCE IN
REGULATORY DECISION MAKING PRELIMINARY REPORT AND RECOMMENDATIONS (2010)
[hereinafter TASK FORCE REPORT].
141. 510(K) REPORT, supra note 139.
142. Id. at 4–5. Specifically, the report indicates that “[a]s the 510(k) standard has been
applied to a wider range of devices over time, including increasingly varied, complex, and
potentially higher-risk technologies, the need for greater clarity with respect to these terms has
become even more pressing.” Id.
143. See infra Figure 2.
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infrastructure to support the development of expertise and information and to
effectuate communication.144 The report defines “new science” as “new data
about the risk/benefit profile of devices; new information about manufacturing
practices and processes; new scientific fields and technologies, such as
nanotechnology; and new regulatory science, including analytic, tools.”145
Specifically, the report presents as a case study a novel technology described
as a device under review by the CDRH that is “a first of a kind device that uses
a new material with unique or unknown biocompatibility properties.”146 The
report gives examples of novel technology within the report as including
advances in nanotechnology and medical robotics.147 As questions of interest,
the report asks what steps should be taken to assure that the novel technologies
or novel uses are safe and effective.148 In order to set the course for future
changes to the 510(k) process, the FDA has published an Action Plan, laying
out twenty-five specific actions to address problems in the current process.149
These include guidance to provide clarity on the 510(k) process, criteria for
identifying “different questions of safety and effectiveness,” and
“technological changes that will generally raise such questions.”150 The FDA
also plans to establish a Center Science Council comprised of external
scientific experts to aid in developing responses to new scientific
information151 and “address[ing] important scientific issues regarding new
medical device technologies.”152 The Action Plan also directs a number of
specific questions to the IOM, including clarification of when a particular
device can no longer be used by a 510(k) applicant as a predicate device for
purposes of substantial equivalence.153
On July 29, 2011, the IOM released its much-anticipated report on the state
of the FDA’s 510(k) process.154 The report came to two core conclusions: (1)
the “510(k) clearance process is not intended to evaluate the safety and
effectiveness of medical devices” and “cannot be transformed into a premarket
144. TASK FORCE REPORT, supra note 140, at 3.
145. Id. at 39.
146. Id. at 45.
147. Id. at 13.
148. Id. at 45.
149. Plan of Action for Implementation of 510(k) and Science Recommendations, U.S. FOOD
& DRUG ADMIN., http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHR
eports/UCM239450.pdf (last visited Nov. 30, 2011).
150. Id. at 2.
151. Id. at 3.
152. Letter from Jeffrey Shuren, Dir., U.S. Food & Drug Admin. Ctr. for Devices &
Radiological Health, to the American Public, available at http://www.fda.gov/downloads/About
FDA/CentersOffices/CDRH/CDRHReports/UCM239451.pdf.
153. Plan of Action for Implementation of 510(k) and Science Recommendations, supra note
149, at 6.
154. INST. OF MED., supra note 3.
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evaluation of safety and effectiveness” as long as substantial equivalence is the
clearance standard;155 and (2) “[i]nformation that would allow an
understanding of the extent to which the 510(k) clearance process either
facilitates or inhibits innovation does not exist.”156 The IOM did not address
the specific questions raised by the FDA in their Action Plan, but considered
them in their assessment.157 The IOM offered eight recommendations to the
FDA, urging that any further investment in remedying the 510(k) process
would not be prudent, in that resources would be better spent developing a new
regulatory framework to replace it.158 These recommendations included
collection of adequate information to guide development of such a new
regulatory framework, implementation of a strategy to collect and assess postmarket information, review of authority in the post-market realm, development
of continuous quality-improvement to track medical devices decisions to assist
in addressing emerging issues, commission of an assessment of the effect of
regulation of devices on innovation, and developing software-specific
procedures.159
These CDRH movements and the IOM report regarding shortcomings in
the 510(k) process generally are extremely relevant to nanotechnology in terms
of the uncertainty surrounding the novelty of the technologies involved, the
lack of metrics to measure and test, and overall challenges in understanding the
differences in scientific and technical aspects of the spectrum of medical
devices incorporating nanotechnology. Specifically, there are significant
questions of whether substantial evidence is appropriate where the links
between the technological differences and safety and efficacy may largely
remain unknown.
C. Biological Products
Biologics are medical products derived from living sources (animals,
human, and microorganisms) and include viruses, therapeutic serums, toxins
and antitoxins, vaccines, blood and blood products, and cells, tissues and gene
therapy products.160 While biologics are regulated similarly to drugs following
1997 amendments to the FDCA and the Public Health Service Act

155. Id. at 193.
156. Id. at 195.
157. Id. at xi–xii.
158. Id. at 7–8.
159. INST. OF MED., supra note 3, at 7–13.
160. A biological product is defined as “virus, therapeutic serum, toxin, antitoxin, vaccine,
blood, blood component or derivative, allergenic product, protein (except any chemically
synthesized polypeptide) or analogous product, or arsphenamine or derivative of arsphenamine
(or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure
of a disease or condition of human beings.” 42 U.S.C. § 262(i) (Supp. IV 2010).
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(“PHSA”),161 there are several important differences between the two. Aside
from their derivation from living sources rather than being chemically
synthesized, biologics differ from traditional small molecule drugs in a number
of ways—they are more complex macromolecular entities, they are typically
manufactured using more sophisticated techniques, and they are more
susceptible to variations in final product due to manufacturing processes,
storage conditions, and interactions with the human body.162 The Center for
Biologics Evaluation and Research (“CBER”) and the CDER jointly handle
biologics.163
The 1902 Biologics Act164 predates the FDCA. The core provisions for the
biologics license process are contained in the PHSA rather than the FDCA; in
1997 the Food and Drug Amendments and Modernization Act165 amended the
PHSA and FDCA to create parallels in the approval processes. A biologics
license application (“BLA”) is issued by the FDA after finding that the product
is safe, pure, and potent and the company assures that the manufacturing
process and facility is adequate.166 Following the 1997 amendments, biologics
approval incorporates classical FDCA provisions and structures of NDAs,
including good manufacturing practice requirements, INDs, post-market
authority, and enforcement mechanisms.167 Biologics are regulated by both the
CDER and CBER and the ultimate approval pathway (BLA or NDA) depends
on the type of product.168 However, these amendments did not include
incorporation of any generic approval process or patent and market exclusivity
provisions for biologics similar to those created by the Hatch-Waxman Act for
drugs.
The ongoing struggle for legislative reform to the U.S, health care system
culminated in the March 23, 2010, enactment of the ACA169 and the partner
Health Care and Education Reconciliation Act of 2010, signed into law on

161. See 42 U.S.C. § 262(a) & note (2006) (Amendments).
162. Paradise, supra note 107, at 281.
163. Transfer of Therapeutic Products to the Center for Drug Evaluation and Research, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalPro
ductsandTobacco/CBER/ucm133463.htm (last visited Jan. 22, 2012) [hereinafter Transfer of
Therapeutic Products].
164. Biologics Control Act of 1902, Pub. L. No. 57-244, 32 Stat. 728.
165. Food and Drug Amendments and Modernization Act, Pub. L. No. 105-115, 111 Stat.
2296 (1997).
166. 42 U.S.C. § 262(a)(2); 21 C.F.R. § 601.2(a) (2010).
167. 42 U.S.C. § 262.
168. The CDER oversees the following products: monoclonal antibodies for in vivo use,
proteins for therapeutic use extracted from animals or micro-organisms (except clotting factors),
growth factors and enzymes, and non-vaccine therapeutic immunotherapies. CBER oversees
allergenics, cellular products, tissue products, gene therapy products, vaccines, and blood &
blood products. Transfer of Therapeutic Products, supra note 163.
169. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010).
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March 30, 2010.170 In addition to extensive provisions aimed at revamping
health insurance, the ACA includes a Biologics Price Competition and
Innovation subtitle, authorizing the FDA to implement a regulatory approval
process for follow-on biologics (also known as biosimilars).171 The impetus to
develop a pathway for biologics akin to the generic drug process was largely
the promise of cost savings.172 The generic drug industry estimates they have
saved the U.S. health care system approximately $734 billion,173 with the first
generic to enter the market generally offering a price twenty-five percent lower
than the pioneer.174 This rises to eighty percent with multiple generics on the
market.175 Biologics, on the other hand, cost an average of twenty-two times
that of ordinary drugs,176 with the eight top selling biologics in 2008 totaling
over $55.6 billion in sales.177 In 2008, twenty-eight percent of the
pharmaceutical industry’s top 100 products came from biologics; projected to
be fifty percent by 2014.178 In 2007, Americans spent $40.3 billion on biologic
drugs (out of a total $286.5 billion for prescription drugs).179 These prices
result in costs to individual patients. For example, Remicade, a treatment for
Rheumatoid arthritis, costs $20,000 per year;180 Herceptin, for treatment of
breast cancer, costs $48,000 per year;181 Humira, for treatment of Rheumatoid
arthritis or Crohn’s disease, costs $50,000 per year;182 and Cerezyme, for
treatment of Gaucher disease, costs $200,000 per year.183
The ACA’s Title VII, Subtitle A, § 7001–7003, amends the PHSA and the
FDCA to create an approval pathway for submission of a product that is

170. Health Care and Education Reconciliation Act, Pub. L. No. 111-152, 124 Stat. 1029
(2010).
171. Patient Protection and Affordable Care Act §§ 7001–03, 124 Stat. at 804–21.
172. Steven Kozlowski et al., Developing The Nation’s Biosimilars Program, 365 NEW ENG.
J. MED. 385, 385 (2011).
173. Anthony D. So & Samuel L. Katz, Op-Ed., Biologics Boondoggle, N.Y. TIMES, Mar. 8,
2010, at A23.
174. U.S. FED. TRADE COMM’N, EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC
DRUG COMPETITION 12 (2009).
175. Id.
176. So & Katz, supra note 173.
177. These biologics were Avastin ($9.2 billion), Enbrel ($8.0 billion), Remicade ($7.9
billion), Humira ($7.3 billion), Rituxan ($7.3 billion), Herceptin ($5.7 billion), Lantus ($5.1
billion), and Epogen/Procrit ($5.1 billion). U.S. FED. TRADE COMM’N, supra note 174, at 5
fig.1-1.
178. So & Katz, supra note 173.
179. FED. TRADE COMM’N, supra note 174, at 3.
180. Id.
181. Id.
182. So & Katz, supra note 173.
183. Id.
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“biosimilar”184 and possibly “interchangeable”185 with an already-approved
biologic. The legislation enables the Secretary of the DHHS to issue guidance
regarding relevant standards and criteria and to implement an approval
processes utilizing public comment.186 The DHHS Secretary delegates this
authority to the Commissioner of the FDA.187 The amendments give much
discretion to the Secretary, and thus the FDA, to determine when clinical
studies may not be necessary for a given submission.188 It also includes
incentives to encourage development of biosimilar products. The amendments
create twelve years of exclusivity for pioneer biosimilar products,189 a one-year
period of exclusivity for the first interchangeable product,190 and an additional
six months of exclusivity for pediatric studies.191 There are also detailed patent
disclosure and litigation provisions.192
Topics currently under consideration by the FDA as they determine how to
implement the new provisions include scientific and regulatory distinctions
between the established generic drug approval processes and the new approval
process for follow-on biologics (focusing on differences between traditional
drugs and biologics based on size, characteristics, complexity, manufacturing
processes, reproducibility, and concepts of similarity and interchangeability)
and data, market, and patent exclusivity concerns.193 It remains to be seen how

184. Biosimilarity means that “the biological product is highly similar to the reference
product notwithstanding minor difference in clinically inactive components” and there are “no
clinically meaningful differences between the biological product and the reference product in
terms of safety, purity, and potency.” 42 U.S.C. § 262(i)(2) (Supp. IV 2010). The biosimilar
must “utilize the same mechanism or mechanisms of action for the condition or conditions of
use” that have been previously approved for the reference product; must have the same route of
administration, dosage form, and strength; and must assure that the product is safe, pure, and
potent. Id. § 262(k)(2)(A)(i).
185. Interchangeability means that biosimilarity is fulfilled and the biologic “may be
substituted for the reference product without the intervention of the health care provider who
prescribed the reference product.” Id. § 262(i)(3). To receive interchangeable status, the
application must include all of the information to show biosimilarity plus: a showing of the
expectation to provide the same clinical result as reference product in any given patient; and a
showing that where “administered more than once to an individual, the risk in terms of safety of
diminished efficacy of alternating or switching between use of the biological product and the
reference product is not greater than the risk of using the reference product without such
alteration or switch.” Id. § 262(k)(4).
186. Id. § 262(k)(8).
187. Richard M. Cooper, Introduction, in FOOD AND DRUG LAW AND REGULATION, 7 (David
G. Adams et al. eds., 2008).
188. 42 U.S.C. § 262(k)(8)(A)–(B).
189. Id. § 262(k)(7)(A).
190. Id. § 262(k)(6)(A).
191. Id. § 262(m)(2)(A).
192. Id. § 262(l).
193. See, e.g., Kozlowski et al., supra note 172.
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this pathway will play out. Thus far, the FDA has formed a Biosimilar
Implementation Committee “to plan the agency’s approach to implementing
the statute in order to ensure that the process of evaluation, review and
approval of products within this newly-defined product category will be
achieved in a consistent, efficient and scientifically sound manner.”194 The
FDA reports formation of a working group195 and the Office of New Drugs
(“OND”) has appointed an Acting Associate Director for Biosimilars to assist
in the coordination of the CDER’s implementation efforts.196 A biosimilars
Review Committee has also been created within the CDER, “serv[ing] in an
advisory capacity to the OND review divisions as they consider sponsor
requests for advice about how to develop a biosimilar product and as they
review biosimilar BLAs.”197 The FDA has also solicited feedback via public
meetings held in Washington, D.C. focusing on multiple aspects of the BPCIA
confronting the FDA, including scientific and technical factors.198
These new follow-on biologic provisions raise interesting questions for
nanomedicine products; the creation of a quicker route to market for products
deemed biosimilar opens up questions regarding measures of “highly similar”
and “interchangeable” that mimic those of substantial equivalence and
bioequivalence in the context of 510(k) cleared medical devices and generic
drugs. Without full-scale purity, potency, and safety requirements as mandated
by the BLA and NDA provisions, follow-on biologics will pose tough
questions for the FDA. One particular area will be that of combination
products, discussed below.
D. Combination Products
The OCP was established in 2002,199 dividing regulatory responsibilities
for products combining elements of drugs, devices, and biologics among the

194. Implementation of the Biologics Price Competition and Innovation Act of 2009, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
ucm215089.htm (last visited Jan. 22, 2012).
195. Id.
196. New Acting Associate Director for Biosimilars in Office of New Drugs, U.S. FOOD &
DRUG ADMIN., (May 17, 2010, 3:29 PM), http://www.fda.gov/AboutFDA/CentersOffices/Office
ofMedicalProductsandTobacco/CDER/ucm217641.htm.
197. Id.
198. Approval Pathway for Biosimilar and Interchangeable Biological Products; Public
Hearing; Request for Comments, 75 Fed. Reg. 61,497 (Oct. 5, 2010).
199. See Medical Device User Fee and Modernization Act of 2002, Pub. L. No. 107-250, sec.
204, § 4(A) 116 Stat. 1588, 1611 (codified at 21 U.S.C. § 353(g)(4)(A) (2006)); see also About
FDA: Office of Combination Products, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/About
FDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordinatio
n/ucm2018184.htm (last visited Jan. 22, 2012). The Safe Medical Device Act of 1990 originally
gave primary jurisdiction to the most relevant center to regulate combination products. Pub. L.
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relevant Centers—CDER, CDRH, and CBER.200 Where a product contains a
drug and a medical device, a drug and a biologic, a medical device and a
biologic, or all three, it is termed a “combination product” and regulated
according to the primary mode of action (“PMOA”).201 The PMOA is defined
as “the single mode of action of a combination product that provides the most
This
important therapeutic action of the combination product.”202
categorization will determine the Center that will oversee the product, as well
as the amount and type of information that the FDA will require.
This collaborative approach to regulation has provided an important
framework for emerging medical technologies that integrate chemical,
mechanical, and biological aspects. However, as acknowledged by the FDA203
and corresponding medical agencies abroad,204 nanotechnology poses a new
set of questions as products at the nanoscale may exhibit much more complex
mechanisms of action(s) not easily quantified or distinguished that do not
adhere to traditional safety, efficacy, or risk measures.205 The major regulatory
challenge for the FDA is the fuzziness between chemical, biological, and
mechanical aspects and modes of action with nanomedicine products and
questions of whether existing safety measures are adequate for novel properties
and interactions at the nanoscale.
Particularly important for emerging nanomedicine developments, the
FDCA distinguishes between the chemical action of drugs and the mechanical
action of medical devices, providing that a device “does not achieve its
primary intended purposes through chemical action within or on the body of
man or other animals and . . . is not dependent upon being metabolized for the
achievement of its primary intended purposes.”206 Cutting-edge nanomedicine
applications in research and development utilize nanoscale properties in a

No. 101-629, sec. 15, § 503(f)(1), 104 Stat. 4511, 4526 (1990) (codified at 21 U.S.C. § 353(f)(1)
(Supp. II 1991)).
200. About FDA: Office of Combination Products, supra note 199.
201. 21 C.F.R. § 3.2(e), (k) (2010).
202. Definition of Primary Mode of Action of a Combination Product, 70 Fed. Reg. 49,848,
49,850 (Aug. 25, 2005). Mode of action is defined as “the means by which a product achieves its
intended therapeutic effect or action” where “‘therapeutic’ action or effect includes any effect or
action of the combination product intended to diagnose, cure, mitigate, treat, or prevent disease,
or affect the structure or any function of the body.” Id.
203. U.S. FOOD & DRUG ADMIN., NANOTECHNOLOGY: A REPORT OF THE U.S. FOOD AND
DRUG ADMINISTRATION NANOTECHNOLOGY TASK FORCE 19–21 (2007), available at
http://www.fda.gov/nanotechnology/taskforce/report2007.pdf.
204. EUR. MEDS. AGENCY COMM. FOR MEDICINAL PRODS. FOR HUMAN USE, REFLECTION
PAPER ON NANOTECHNOLOGY-BASED MEDICINAL PRODUCTS FOR HUMAN USE 4 (2006).
205. For the earliest discussion of these problems in the legal literature, see Frederick A.
Fielder & Glenn H. Reynolds, Legal Problems of Nanotechnology: An Overview, 3 S. CAL.
INTERDISC. L.J. 593 (1994).
206. 21 U.S.C. § 321(h) (2006).
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manner that integrate chemical, mechanical, and biological with optical,
thermal, and other properties to respond to a given environment or outcome
once deployed into the body.207 A single product may initially target specific
organs and tissues in the human body, image them or take vitals, diagnose
medical conditions, and subsequently provide medical therapies or evolve to
address the status detected once deployed into the human body. Rigid
categories and time-limited assessment regarding chemical and mechanical
aspects, as well as the identification of the primary mode of action, may hinder
appropriate classification of evolving nanomedical products and lead to
underregulation of novel applications.
III. LEGAL AND REGULATORY RESPONSES TO NANOTECHNOLOGY
The evolution of nanotechnology over the last few decades has met with
little attention from the FDA and other federal agencies until about 2000. This
is chiefly because the unifying term “nanotechnology” was not in widespread
use until the National Science Foundation began using it to package and
promote once disparate areas of scientific research into one unifying field
based on the size and novel characteristics displayed at the nanoscale.208 With
the establishment of the NNI and a resulting massive yearly infusion of
funding for research, development, and education, nanotechnology was thrust
onto the radar of researchers, industry, and invariably the American public.
Despite rapid advances and the infusion of federal dollars into funding, not
all coverage of nanotechnology has been positive nor is there unanimous
support for the U.S. government’s aggressive funding efforts. Many
commentators proffer that nanotechnology research and development is too
risky for workers exposed to nanoparticles and nanomaterials as well as
consumers and the general population, based on a lack of information on
toxicological, biological, environmental, and ecological effects of particles and
materials at the nanoscale.209 Some have urged the application of the
precautionary principle, a cry parallel to that of a previous decade in the United
States (and adopted in the European Union) regarding genetically modified
foods—that no nanotechnology be developed or utilized until it is shown to be

207. See, e.g., Nat’l Cancer Inst. Alliance for Nanotechnology, Nanoshells, NAT’L CANCER
INST., http://nano.cancer.gov/learn/understanding/nanotech_nanoshells.asp (last visited Nov. 30,
2011).
208. See National Nanotechnology Initiative, NAT’L SCI. FOUND., www.nsf.gov/crssprgm/
nano/ (last updated June 17, 2011).
209. For a discussion of perspectives on nanotechnology risk, see ANDREW D. MAYNARD,
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY: A RESEARCH STRATEGY
FOR ADDRESSING RISK (Project on Emerging Nanotechnologies, PEN 3, 2008) [hereinafter
MAYNARD, ADDRESSING RISK]; see also Andrew D. Maynard, Nanotechnology: The Next Big
Thing, or Much Ado About Nothing?, 51 ANNALS OCCUPATIONAL HYGIENE 1 (2007).
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absolutely safe.210 Numerous reports from researchers warn that nanoparticles
may have neurological and biological effects similar to asbestos and that the
long-term use of nanoproducts could have far-reaching negative impact on the
environment as they are excreted or otherwise expelled from the body or from
consumer products.211 While compelling, these concerns are beyond the scope
of this Article, and are addressed elsewhere.
Academics, professional organizations, government bodies, and non-profit
institutions alike have assessed and written on the adequacy of existing legal
and regulatory frameworks for nanotechnology, highlighting gaps in the
science and oversight, and identifying aspects necessitating particular
investigation.212 While nanotechnology necessarily crosses multiple agencies

210. Robert F. Service, Nanotechnology Grows Up, 304 SCI. 1732, 1733–34 (2004).
211. For toxicology research on fullerenes, see, for example, J.D. Fortner et al., C60 in Water:
Nanocrystal Formation and Microbial Response, 39 ENVTL. SCI. & TECH. 4307 (2005); Sarah B.
Lovern & Rebecca Klaper, Dahnia Magna Mortality when Exposed to Titanium Dioxide and
Fullerene (C60) Nanoparticles, 25 ENVTL. TOXICOLOGY & CHEMISTRY 1132 (2006); Eva
Oberdörster, Manufactured Nanomaterials (Fullerenes, C60) Induce Oxidative Stress in the Brain
of Juvenile Largemouth Bass, 112 ENVTL. HEALTH PERSP. 1058 (2004). For toxicology research
on carbon nanotubes, see Craig A. Poland et al., Carbon Nanotubes Introduced into the
Abdominal Cavity of Mice Show Asbestos-Like Pathogenicity in a Pilot Study, 3 NATURE
NANOTECHNOLOGY 423 (2008); Lin Zhu et al., DNA Damage Induced by Multiwalled Carbon
Nanotubes in Mouse Embryonic Stem Cells, 7 NANO LETTERS 3592 (2007).
212. See, e.g., LINDA K. BREGGIN & JOHN PENDERGRASS, WOODROW WILSON INT’L CTR.
FOR SCHOLARS, WHERE DOES THE NANO GO? END-OF-LIFE REGULATION OF NANOTECHNOLOGIES (Project on Emerging Nanotechnologies, PEN 10, 2007); J. CLARENCE DAVIES,
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY OVERSIGHT: AN AGENDA
FOR THE NEW ADMINISTRATION (Project on Emerging Nanotechnologies, PEN 13, 2008); J.
CLARENCE DAVIES, WOODROW WILSON INT’L CTR. FOR SCHOLARS, EPA AND
NANOTECHNOLOGY: OVERSIGHT FOR THE 21ST CENTURY (Project on Emerging
Nanotechnologies, PEN 9, 2007); J. CLARENCE DAVIES, WOODROW WILSON INT’L CTR. FOR
SCHOLARS, MANAGING THE EFFECTS OF NANOTECHNOLOGY (Project on Emerging
Nanotechnologies, PEN 2, 2006); E. MARLA FELCHER, WOODROW WILSON INT’L CTR. FOR
SCHOLARS, THE CONSUMER PRODUCT SAFETY COMMISSION AND NANOTECHNOLOGY (Project
on Emerging Nanotechnologies, PEN 14, 2008); MARK GREENWOOD, WOODROW WILSON INT’L
CTR. FOR SCHOLARS, THINKING BIG ABOUT THINGS SMALL: CREATING AN EFFECTIVE
OVERSIGHT SYSTEM FOR NANOTECHNOLOGY (Project on Emerging Nanotechnologies, PEN 7,
2007); SAMUEL N. LUOMA, WOODROW WILSON INT’L CTR. FOR SCHOLARS, SILVER
NANOTECHNOLOGIES AND THE ENVIRONMENT: OLD PROBLEMS OR NEW CHALLENGES? (Project
on Emerging Nanotechnologies, PEN 15, 2008); MAYNARD, ADDRESSING RISK, supra note 209;
NANOACTION, INTERNATIONAL CENTER FOR TECHNOLOGY ASSESSMENT, PRINCIPLES FOR THE
OVERSIGHT OF NANOTECHNOLOGIES AND NANOMATERIALS (2007) available at http://www.icta.
org/doc/Principles%20for%20the%20Oversight%20of%20Nanotechnologies%20and%20Nanom
aterials_final.pdf; NAT’L NANOTECHNOLOGY INITIATIVE, NAT’L SCI. & TECH. COUNCIL,
ENVIRONMENTAL, HEALTH, AND SAFETY RESEARCH NEEDS FOR ENGINEERED NANOSCALE
MATERIALS (2006) available at http://www.nano.gov/NNI_EHS_research_needs.pdf; NAT’L
RES. COUNCIL, REVIEW OF THE FEDERAL STRATEGY FOR NANOTECHNOLOGY-RELATED
ENVIRONMENTAL, HEALTH, AND SAFETY RESEARCH (2008); WILLIAM B. SCHULTZ & LINDA
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that regulate public and worker safety, the environment, national security, and
consumer products, the FDA will oversee the majority of nanomedicine
products on the market.
Although extremely incremental, the FDA has initiated some agency
information-gathering actions to begin to contemplate novel issues raised by
nanotechnology products and applications. The FDA has installed a
Nanotechnology Task Force,213 fostered intra-agency Center collaborations,
begun to implement internal agency policies relating to nanotechnology, and
published draft guidance for industry.214 Specifically, in May 2010, the FDA’s
CDER and the Research Office of Pharmaceutical Science issued a policy
instructing drug reviewers to collect nanospecific information from new drug
applications.215 To date, the CDER is the only Center to adopt internal policy
regarding nanotechnology.
Although this section will primarily focus on FDA responses to
nanotechnology, an initial examination of international, state, and local
government actions are instructive to highlight how the piecemeal and
uncoordinated efforts at information-gathering and oversight have thus far
progressed.
A.

State, Local, and International

In light of the lack of nano-specific oversight mechanisms at the federal
level, the City of Berkeley and the State of California have taken small steps in
gathering information on nanotechnology in order to track its use by mandating
the reporting of nanoparticle and nanomaterial manufacturing. Berkeley,

BARCLAY, WOODROW WILSON INT’L CTR. FOR SCHOLARS, A HARD PILL TO SWALLOW:
BARRIERS TO EFFECTIVE FDA REGULATION OF NANOTECHNOLOGY-BASED DIETARY
SUPPLEMENTS (Project on Emerging Nanotechnologies, PEN 17, 2009); MICHAEL R. TAYLOR,
WOODROW WILSON INT’L CTR. FOR SCHOLARS, ASSURING THE SAFETY OF NANOMATERIALS IN
FOOD PACKAGING: THE REGULATORY PROCESS AND KEY ISSUES (Project on Emerging
Nanotechnologies, PEN 12, 2008); MICHAEL R. TAYLOR, WOODROW WILSON INT’L CTR. FOR
SCHOLARS, REGULATING THE PRODUCTS OF NANOTECHNOLOGY: DOES FDA HAVE THE TOOLS
IT NEEDS? (Project on Emerging Nanotechnologies, PEN 5, 2006) [hereinafter TAYLOR,
REGULATING THE PRODUCTS OF NANOTECHNOLOGY]; U.S. ENVTL. PROT. AGENCY,
NANOTECHNOLOGY WHITE PAPER (2007), available at http://es.epa.gov/ncer/nano/publications/
whitepaper12022005.pdf; Kenneth W. Abbott et al., A Framework Convention for
Nanotechnology?, 36 Envtl. L. Rep. (Envtl. Law Inst.) 10,931 (2006); Jordan Paradise et al.,
Developing Oversight Frameworks for Nanobiotechnology, 9 MINN. J. L. SCI. & TECH. 399
(2008); Mihail C. Roco, Possibilities for Global Governance of Converging Technologies, 10 J.
NANOPARTICLE RES. 11 (2008); ABA Section of Env’t, Energy, & Res., Nanotechnology
Project, ABA, http://www.americanbar.org/groups/environment_energy_resources/projects_
awards/nanotech.html (last visited Nov. 30, 2011).
213. U.S. FOOD & DRUG ADMIN, supra note 203, at 5.
214. See infra Part III.C.2–4.
215. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 3–4.
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California requires that manufacturers report yearly to the Toxics Management
Division on certain aspects of their manufacturing processes and products.216
The California Department of Toxic Substances and Control issued letters in
January 2009 to select manufacturers identified as producing nanoparticles or
nanomaterials, requesting nano-specific data on carbon nanotubes and methods
of worker protection.217 The California legislature had authorized the
Department to request information on chemicals of concern.218 In a joint effort
with the California Council on Science and Technology, the California
Department of Toxic Substances issued a report in January 2010 detailing
enabling legislative provisions, areas of inquiry, and the general status of
nanotechnology research and manufacturing in California.219 To date, no other
state or municipality has followed California’s lead.
Internationally, other countries are also at early stages of understanding the
scope of the unique legal and scientific questions that nanotechnology may
raise. While no countries have enacted nano-specific legislation, there have
been some efforts to initiate reporting and tracking mechanisms. A voluntary
reporting scheme was implemented in the United Kingdom, but published
reports indicate that authorities received an abysmally low number of
submissions in response.220 In 2004, the Royal Society and Royal Academy of
Engineering were commissioned by the British government to examine
oversight of manufactured nanoparticles and recommended that a ban on free
(rather than fixed in a matrix) manufactured nanoparticles in environmental
applications be implemented;221 there has been no movement to implement that
ban.222 It appeared from media reports in 2009 that Canada was to claim the

216. BERKELEY, CAL., MUNICIPAL CODE §§ 15.12.040(I), 15.12.050(C)(7) (2008).
217. Carbon Nanotube Information Call-in, CAL. DEP’T OF TOXIC SUBSTANCES CONTROL,
http://www.dtsc.ca.gov/TechnologyDevelopment/Nanotechnology/CNTcallin.cfm (last visited
Nov. 30, 2011). The Department’s future schedule of inquiry to manufacturers in the state over
the next few years includes nano silver, reactive nonmetals, dendrimers, and quantum dots.
218. CAL. HEALTH & SAFETY CODE §§ 57019–57020 (West Supp. 2011).
219. CAL. COUNCIL ON SCI. AND TECH., NANOTECHNOLOGY IN CALIFORNIA (2010),
available at http://www.ccst.us/publications/2010/2010Nano.pdf.
220. DEP’T FOR ENV’T, FOOD & RURAL AFFAIRS, UK VOLUNTARY REPORTING SCHEME FOR
ENGINEERED NANOSCALE MATERIALS 4 (2008) (U.K.), available at http://www.defra.gov.uk/en
vironment/nanotech/policy/pdf/vrs-nanoscale.pdf; Archive: Nanotechnology: Policy, DEP’T FOR
ENV’T, FOOD AND RURAL AFFAIRS, http://archive.defra.gov.uk/environment/quality/nanotech/
policy.htm (last visited Nov. 30, 2011) (stating that DEFRA received only thirteen submissions
during the two years of the study).
221. THE ROYAL SOC’Y & THE ROYAL ACAD. OF ENG’G, NANOSCIENCE AND
NANOTECHNOLOGIES: OPPORTUNITIES AND UNCERTAINTIES 85 (2004), available at
http://www.nanotec.org.uk/report/Nano%20report%202004%20fin.pdf.
222. Although the U.K. government issued a response, no further information is available.
See The Royal Soc’y & The Royal Acad. of Eng’g, Nanotechnology and Nanoscience,
NANOTEC.ORG, http://www.nanotec.org.uk/govRes.htm (last visited Nov. 30, 2011).
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role of being the first country to enact law regarding reporting and monitoring
of nanomaterials,223 although the bill has yet to become law. Bill C-494,
introduced in March 2010, would have amended the Canadian Environmental
Protection Act.224
Australia commissioned Monash University academics to examine that
country’s existing legal frameworks; they concluded that there were significant
gaps when those frameworks were applied to nanotechnology.225 The
European Economic and Social Committee of the European Parliament
recommended in a 2005 opinion that the European Commission develop
methods to identify nanotechnology risks, setting a recommended timeframe of
2008.226 Similar to many other countries and regions examining these issues in
terms of law and regulations, the European Parliament has not yet responded.
B.

Federal Administrative Agencies

As nanotechnology is truly a convergence of scientific fields and
disciplines, spanning a vast spectrum of research and product development
both in the United States and internationally, U.S. federal agencies have
struggled to keep abreast of the rapidly increasing scientific and technological
capabilities, applications, and marketed consumer products at the nanoscale.
In the face of myriad unknowns regarding health and environmental effects of
nanoparticles and nanomaterials, federal agencies have proceeded to measure,
evaluate, approve, and monitor nanotechnology processes and products under
existing legal and regulatory frameworks. Although a number of U.S. federal
regulatory agencies have taken the initiative to either implement voluntary
nanotechnology-specific reporting mechanisms,227 begin expert investigations

223. Victoria Gill, Nanotechnology Regulation Creeps Closer, CHEMISTRY WORLD (Feb. 25,
2009), http://www.rsc.org/chemistryworld/News/2009/February/25020901.asp.
224. See An Act to Amend the Canadian Environmental Protection Act, 1999,
(nanotechnology), Bill C-494 (Historical), 40th Parl., 3d. Session (Can. 2010), available at
http://parl.gc.ca/content/hoc/Bills/403/Private/C-494/C-494_1/C-494_1.pdf.
225. KARINNE LUDLOW ET AL., A REVIEW OF POSSIBLE IMPACTS OF NANOTECHNOLOGY ON
AUSTRALIA’S REGULATORY FRAMEWORK 8, 100 (2007), available at http://www.innovation.
gov.au/Industry/Nanotechnology/NationalEnablingTechnologiesStrategy/Documents/MonashRep
ort2007.pdf.
226. Opinion of the European Economic and Social Committee on the ‘Communication from
the Commission to the Council, the European Parliament and the Economic and Social
Committee—Nanosciences and Nanotechnologies: An action Plan for Europe 2005-2009,’ 2006
O.J. (C 185) 1, available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2006:
185:0001:0009:en:pdf.
227. Although subsequently acknowledging that it has largely failed, EPA instituted a
voluntary program for industry to provide information relevant to health and safety for industrial
applications of nanotechnology and nanomaterials. OFFICE OF POLLUTION PREVENTION &
TOXICS, U.S. ENVT’L PROT. AGENCY, NANOSCALE MATERIALS STEWARDSHIP PROGRAM:
INTERIM REPORT 3, 6 (2009), available at http://epa.gov/oppt/nano/nmsp-interim-report-final.pdf.
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into specific questions regarding nanotechnology safety or risks,228 clarify
existing regulations and policies in light of nanotechnology,229 or create
internal methods of categorizing nanotechnology developments or products
within their purview,230 for the most part agencies are operating on a business
as usual mode for nanotechnology.
Specifically, the EPA has published two notices in the Federal Register
applicable to nanotechnology products. The first instructs that the EPA will
regulate engineered carbon nanotubes under the Toxic Substances Control
Act.231 The second clarifies that the Federal Insecticide Fungicide and
Rodenticide Act applies to product claims involving ion-generating silver
pesticides.232 This clarification notice for silver pesticides, while not specific
to nanotechnology, was a response to petitions regarding Samsung’s marketing
claims that its silver ion-generating washing machine utilized nanotechnology
in the form of germ-killing silver nanoparticles.233
The U.S. Patent and Trademark Office (“USPTO”) has also taken steps to
deal with the expanse of nanotechnology patent applications by creating a
nanotechnology patent class. One source reports that the USPTO began
issuing nanotechnology-related patents as early as 1976.234 In developing a
nanotechnology classification system, the USPTO created a framework that
attempts to advance uniformity in classifying nanopatents in an effort to
standardize the terminology, create an effective system for disclosure and
cross-referencing, assist inventors and examiners in identifying and reviewing

228. U.S. FOOD & DRUG ADMIN., supra note 203, at 20.
229. Toxic Substances Control Act Inventory Status of Carbon Nanotubes, 73 Fed. Reg.
64,946 (Oct. 31, 2008); Pesticide Registration; Clarification for Ion-Generating Equipment, 72
Fed. Reg. 54,039 (Sept. 21, 2007).
230. See, e.g., MAPP 5015.9 REPORTING FORMAT, supra note 21, at 4–5; U.S. PATENT &
TRADEMARK OFFICE, CLASSIFICATION DEFINITIONS: CLASS 977 NANOTECHNOLOGY (2010),
available at http://www.uspto.gov/web/patents/classification/uspc977/defs977.pdf [hereinafter
CLASS 977 DEFINITIONS].
231. Toxic Substances Control Act Inventory Status of Carbon Nanotubes, 73 Fed. Reg. at
64,946.
232. Pesticide Registration; Clarification for Ion-generating Equipment, 72 Fed. Reg. at
54,039.
233. Susan Morrissey, Reclassifying Nanosilver: EPA Will Now Consider Nanosilver Used in
Washing Machines as Pesticides, CHEMICAL & ENG’G NEWS, Dec. 4, 2006, at 14, 14, available
at http://pubs.acs.org/cen/news/84/i49/8449notw7.html (last visited Nov. 30, 2011).
234. Tyson Winarski & Elizabeth Stoker-Townsend, Nanotechnology Thriving on Patents,
INTELL. PROP. TODAY, Apr. 2005, at 26, 26 (attributing information to the National Science
Foundation). However, the first patent within the USPTO patent classification system was filed
in September 1975 and issued in August 1978. Injectable Compositions, Nanoparticles Useful
Therein, and Process of Mfg. Same, U.S. Patent No. 4,107,288 (filed Sept. 9, 1975).
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relevant prior art, and decrease inadvertent patent infringement.235 As a result
of the USPTO’s efforts, there are currently over 7410 patents classified as
nanotechnology-related inventions236 under five broadly delineated areas,237
divided into 263 subclasses.238
While suffering from numerous
shortcomings,239 these actions by the USPTO serve as an example for other

235. Jordan Paradise, Claiming Nanotechnology: Improving USPTO Efforts at Classification
of Emerging Nano-Enabled Pharmaceutical Technologies, 10 NW. J. TECH. & INTELL. PROP.
169, 184 (2012).
236. This number is based on the author’s search of the USPTO website at http://patft.uspto.
gov/netahtml/PTO/search-adv.htm using the “Advanced Search” function and the 977
classification as the single search term (enter ccl/977/$ into the query box). An identical search
of the published patent applications at http://appft1.uspto.gov/netahtml/PTO/search-adv.html
identified 10,613 applications that fall into the 977 classification. Searches performed Nov. 30,
2011.
237. CLASS 977 DEFINITIONS, supra note 230. The five broad areas under the 977 class are:
(1) nanostructures and chemical compositions; (2) devices that include at least one nanostructure;
(3) mathematical algorithms; (4) methods or apparatuses for making, detecting, analyzing or
treating nanostructure; (5) and specified uses of nanostructures. Id.
238. These Class 977 cross-reference art collection subclasses span sections 700–963. Id. at
977-10 to -40.
239. Despite the nascent state of patent litigation involving the scale or characteristics of
nanotechnology in the realm of nanomedicine, the scholarly literature has identified several
concerns that will emerge as patenting continues. The first major concern is overlapping claims
that will occur as the result of broad claiming of early patents and the increased understanding of
the properties and functioning at the nanoscale that were unknown in decades past. For example,
early patent claims may conflate the macro, micro, and nanoscale in a manner that is problematic
for later inventions that identify and harness something present at a range in the nanoscale and not
at the micro or macro scale. Another concern is the convergence of technologies at the nanoscale,
in that overlapping patents and claims may cross multiple technologies, with many issued before
“nano” was a widespread word. Many of these concerns will abate given the USPTO’s
classification system as patenting moves forward, although questions will arise with regard to
inventions submitted and patents issued prior to the development of the classification system. In
performing the cross-listing classifications, the USPTO is merely putting issued patents into those
263 subclasses and not making determinations on claim scope and potential infringement from
one patent to the next, except as part of the evaluation of prior art. For academic perspectives,
see, for example, Indrani Barpujari, The Patent Regime and Nanotechnology: Issues and
Challenges, 15 J. INTELL. PROP. RTS. 206 (2010); Diana M. Bowman & Graeme A. Hodge, A
Small Matter of Regulation: An International Review of Nanotechnology Regulation, 8 COLUM.
SCI. & TECH. L. REV. 1 (2007); K. Eric Drexler & Jason Wejnert, Nanotechnology and Policy, 45
JURIMETRICS J. 1 (2004); Fiedler & Reynolds, supra note 205; Ernest J. Getto et al.,
Nanotechnology: Will Tiny Particles Create Large Legal Issues?, SCITECH LAW., Summer 2009,
at 6; Mark A. Lemley, Patenting Nanotechnology, 58 STAN. L. REV. 601 (2005); Thomas M.
Mackey, Nanobiotechnology, Synthetic Biology, and RNAI: Patent Portfolios for Maximal NearTerm Commercialization and Commons for Maximal Long-Term Medical Gain, 13 MARQ.
INTELL. PROP. L. REV. 123 (2009); Glenn Harlan Reynolds, Nanotechnology and Regulatory
Policy: Three Futures, 17 HARV. J.L. & TECH. 179 (2003); Douglas J. Sylvester & Diana M.
Bowman, Navigating the Nanotechnology Patenting Landscape: English Garden or Tangled
Grounds?, in BIOMEDICAL NANOTECHNOLOGY 359 (Methods in Molecular Biology, No. 726,
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federal agencies in terms of gathering information relevant to nanotechnology
and categorizing nano-specific features that could be useful in the future as
more becomes known about products, uses, and potential risks of
nanotechnology. Utilization and effective linking of this information among
agencies could serve as a mechanism to fill in the information gaps currently
confronting other relevant agencies.
Aside from these actions by the EPA, the USPTO, and, as described
below, the FDA, thus far federal executive agencies responsible for the
oversight of the spectrum of nanotechnology products have utilized existing
laws, regulations, policy, and institutional structures to govern these products.
The authority of these agencies and the administrative tools available to them
are diverse and vary greatly across domains. Basic administrative law
concepts instruct that federal agencies operate within the authority vested in
them by Congress under the enabling statute and subsequent statutes, and
construed by the courts. Agencies are able to promulgate regulations or
adjudicate individual instances within the bounds of this authority and mandate
from Congress. Agency policy and procedures, public and internal guidance,
advisory opinions, and a variety of other agency documents serve to clarify and
interpret statutes and regulations; while not having the force of law, these
documents all contribute to “oversight” in a broad sense.
This section has focused on a discussion of the creation and application of
agency-promulgated regulations, the development of public and internal
guidance, as well as methods of information gathering that agencies have
initiated in the nanotechnology realm such as reporting mechanisms and
internal classification schemes. Part III.C and Part IV will address the capacity
of the current statutory and regulatory scheme to deal with nanotechnology.
This Article urges that the FDA’s broad mandate from Congress and scope of
authority with regard to drugs, medical devices, and biologics provide ample
opportunity for the Agency to develop requirements for enhanced data and
information from industry to inform its assessment of the characteristics and

Sarah J. Hurst ed. 2011); Georgios I. Zekos, Patenting Abstract Ideas in Nanotechnology, 9 J.
WORLD INTELL. PROP. 113 (2006). For practitioner perspectives, see, for example, Laurie A.
Axford, Patent Drafting Considerations for Nanotechnology Inventions, 3 NANOTECHNOLOGY L.
& BUS. 305 (2006); Raj Bawa, Nanotechnology Patenting in the US, 1 NANOTECHNOLOGY L. &
BUS. 31 (2004); Matthew J. Dowd et al., KSR International Co. v. Teleflex Inc.: Another Small
Issue for Nanotechnology?, 4 NANOTECHNOLOGY L. & BUS. 293 (2007); Drew Harris et al.,
Strategies for Resolving Patent Disputes Over Nanoparticle Drug Delivery Systems, 1
NANOTECHNOLOGY L. & BUS. 372 (2004); Vivek Koppikar et al., Current Trends in Nanotech
Patents: A View From Inside the Patent Office, 1 NANOTECHNOLOGY L. & BUS. 24 (2004) John
Josef Molenda, The Importance of Defining Novel Terms in Patenting Nanotechnology
Inventions, 1 NANOTECHNOLOGY L. & BUS. 174 (2004); Sean O’Neill et al., Broad Claiming in
Nanotechnology Patents: Is Litigation Inevitable?, 4 NANOTECHNOLOGY L. & BUS. 29 (2007).
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properties of nanotechnology products, as well as the assessment of both short
and long-term public health effects.
C. The Food and Drug Administration
The FDA utilizes existing statutory provisions240 and regulatory pathways
to review nanomedicine products falling within its oversight.241 This has
provoked debate from those that believe that nanotechnology warrants its own
oversight provisions.242 The FDA and other agencies struggle with a dearth of
observed or reported health or safety issues traceable to any nanocharacteristics of a product; this serves as the basis of the FDA’s position that
the current system thus far provides adequate assurances for safety and
efficacy in the case of new drugs and high risk medical devices,
bioequivalence in the case of generic drugs, and substantial equivalence in the
case of lower risk medical devices.243
Nanotechnology-based research and development activity in medical and
health applications is booming. While many nanotechnology-based medical
device products are entering the market (such as in vitro diagnostics and
imaging tools, dental products, bone repair systems, and tissue reinforcement
products), nanomedicine is currently dominated by drugs and drug-delivery
applications, accounting for about three-quarters of the emerging
These rapidly developing applications in
nanomedicine market.244
nanomedicine often integrate mechanical, chemical, electrical, and optical
properties at the nanoscale.245 As discussed previously, unlike products at the
macroscale and microscale, the distinction between chemical and mechanical
action are not easily distinguishable or measurable at the nanoscale.246 While
this distinction between chemical, electrical, mechanical, and optical properties
is not critical for the science to evolve, it is extremely important in determining
which regulatory pathway a company will need to pursue for any given
product, as the dividing line between a drug and a device has traditionally been
drawn in terms of whether it acts chemically (is metabolized by the body) or

240. Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§ 301–99 (2006).
241. See infra Figures 1 & 2.
242. See, e.g., International Center for Technology Assessment et al., Citizen Petition, FDA
Docket No. 2006P-0210, at 3–4, 22 (May 16, 2006), available at http://www.fda.gov/ohrms/
dockets/dockets/06p0210/06p-0210-cp00001-01-vol1.pdf.
243. See U.S. FOOD & DRUG ADMIN., supra note 203, at 17–18, 22, 24, 32 (noting lack of
appropriate testing specifically tailored to nano-scale, as opposed to larger, particles and outlining
current testing and regulatory procedures). The Task Force report does not deal with biosimilars
specifically as the report was issued three years before the legislation creating the biosimilars
pathway. Implementation of those provisions is pending.
244. Wagner et al., supra note 42, at 1211.
245. See infra Part III.C.1.
246. Fiedler & Reynolds, supra note 205, at 608–09.
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mechanically.247 This ties directly to categorization as a drug, device, or
biologic, and whether abbreviated routes to market are available.
The FDA has taken the following steps with regard to nanotechnology:
forming a multi-center task force, instituting a CDER-specific internal policy,
publishing draft guidance for industry, soliciting public comments through
public meetings, and partnerships with research institutions to examine
particular aspects of nanotechnology.
1.

Nanotechnology Task Force

An FDA Task Force was convened in response to several citizen petitions
aimed at perceived gaps in oversight for consumer products containing
nanoparticles.248 To investigate generally whether existing provisions continue
to encourage development of safe, effective and innovative products using
nanotechnology and also address specific issues raised in the petitions, the
FDA established the Nanotechnology Task Force comprised of authorities in
the CBER, CDER, and CDRH.249 In July 2007, the FDA’s Nanotechnology
Task Force issued a report indicating that no new regulatory categories were
needed for drug, medical device, and food products that contained
nanoparticles or nanomaterials or were manufactured using nanotechnology.250
However, the report also urged that the Agency must continuously monitor and
understand the science in order to appropriately apply regulations in the future
and suggested that Centers should consider issuing guidance for industry.251
The report flagged combination products utilizing nanoscale materials as
potentially problematic, acknowledging novel issues for regulation due to their
dynamic quality based on size and “their potential for diverse applications.”252
Specifically, it provided:
The very nature of nanoscale materials—their dynamic quality as the size of
nanoscale features change, for example, and their potential for diverse
applications—may permit the development of highly integrated combinations
of drugs, biological products, and/or devices, having multiple types of uses,
such as combined diagnostic and therapeutic intended uses. As a consequence,
the adequacy of the current paradigm for selecting regulatory pathways for
“combination products” may need to be assessed to ensure predictable

247. Id.
248. Press Release, U.S. Food & Drug Admin., FDA Forms Internal Nanotechnology Task
Force (Aug. 9, 2006), available at http://www.fda.gov/ohrms/dockets/ac/06/briefing/20064241B1-02-33-FDA-Nano%20FDA%20News%20release.pdf.
249. U.S. FOOD & DRUG ADMIN., supra note 203, at 5.
250. Id. at 30, 35.
251. Id. at 15, 33.
252. Id. at 20.
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determinations of the most appropriate pathway for such highly integrated
253
combination products.

2.

CDER Manual of Policies and Procedures

Specific to drugs, the FDA’s CDER and the Research Office of
Pharmaceutical Science issued an internal Manual of Policies and Procedures
(“MaPP”) in May 2010 that instructs drug reviewers to capture “relevant
information about nanomaterial-containing drugs” that will be entered into a
nanotechnology database.254 The MaPP states that “in order to develop
guidance for industry, CDER needs to organize all the data submitted in
support of nanotechnology-based drug applications,”255 gather all “relevant
information about nanomaterial-containing drugs” and enter them into a
nanotechnology database maintained by the Agency.256 Of interest for the
synthesis of data at the nanoscale, the MaPP defines the terms
nanomaterial/nanoscale material (“[a]ny materials with at least one dimension
smaller than 1,000nm”); nanomedicine (“[t]he use of nanoscale materials for
medical applications”); and characterization (“[p]hysicochemical evaluation of
relevant drug properties”).257
An important feature of the MaPP definitions is the range included in the
CDER’s conception of nanoscale as 1–1,000nm compared to the NNI
definition extending from 1–100nm.258 This range suggests that the FDA has
determined, as many scientists have argued for years,259 that nanotechnology
cannot be fit precisely into a range under 100nm, as the size-dependent novel
properties vary with the material, environment, and interactions. While this
MaPP serves an internal information-gathering purpose and imposes no
additional requirements on drug applicants, it signals recognition of the nascent
state of understanding of the complex science of nanotechnology in human
drugs.
The MaPP provides several attachments that drug reviewers are instructed
to complete for each drug application falling into the nanoscale classification.
The first is a list of nanotechnology product evaluation questions.260 These
questions include identification of the type of nanoscale materials in the
product, whether it is a reformulation of a previously-approved product,

253. Id. at 20–21 (footnote omitted).
254. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 1.
255. Id. at 2.
256. Id. at 1.
257. Id. at 3.
258. See supra Part I.
259. Opinion of the Scientific Committee on Emerging and Newly Identified Health Risks on
the Scientific Basis for the Definition of the Term ‘Nanomaterial’, at 13 (Dec. 8, 2010), available
at http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_032.pdf.
260. MAPP 5015.9 REPORTING FORMAT, supra note 21, at 6.
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whether it is soluble or insoluble in an aqueous environment, the range of the
nanomaterial, the reported particle size, other reported properties, and methods
used to characterize the nanomaterial.261 Another attachment details the
template for the format of the drug product database entry, including basic
descriptions of the product (e.g., drug name, indication, route of
administration, sponsor, approval date, Center division), particle size range,
and technique for assessing the nanospecific properties.262 The database entry
also includes website links to quality reviews, clinical reviews, ClinPharm
reviews, and PharmTox reviews.263 These last four database entries could be
especially useful for ongoing evaluation of the toxicological effects and crosslinking of similar products either by FDA or outside experts or advisory
committees if made publically available or available to a segment of
specialists. A third attachment provides a product review flow chart,
visualizing the series of questions posited in the first attachment
questionnaire.264
While this internal procedure is in early stages, it has the potential to
generate an abundance of nano-specific information in the context of drug
products approved by the CDER. Other FDA Centers should implement
similar procedures for products within their regulatory authority, using the
CDER MaPP as a guide for structuring this information. This will be
particularly illuminating for post-market tracking of combination
nanotechnology products that are classified for oversight purposes by their
PMOA; it may be that as information accumulates regarding patient use and
potentially adverse events that the FDA may want to reassess the use of PMOA
measures for nanotechnology-based nanomedicine products. For example,
where a nano combination product is classified as a medical device based on
its mechanical properties rather than a drug based on its chemical properties
(which would mandate more extensive clinical trials to satisfy safety and
efficacy measures), it may later become apparent through post-market studies
or event reporting that the unique characteristics that make the product “nano”
behave in a manner that necessitates a drug-like approval process instead to
most adequately assure safety and efficacy.
3.

Draft Guidance for Industry

On June 9, 2011, the FDA released draft guidance for industry laying out
the Agency’s “current thinking on whether FDA-regulated products contain

261. Id.
262. Id. at 8. A subsequent attachment lays out the common techniques utilized for
nanomaterial characterization, including abbreviations. Id. at 10.
263. Id. at 8.
264. Id. at 9.
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nanomaterials or otherwise involve the application of nanotechnology.”265 The
guidance urges that the document does not establish legally enforceable
obligations, but should be viewed only as recommendations for the industry.266
It “does not establish any regulatory definitions” or “address the regulatory
status of products,” but does state that future additional guidance may be
issued for specific product or classes of products.267 Published concurrently
with an announcement on policy principles for nanotechnology regulation from
the Office of Science and Technology Policy (“OSTP”),268 the draft guidance
exemplifies the ongoing battle by federal administrative agencies to quantify,
categorize, and regulate nanotechnology. The deadline for written comments
was August 15, 2011.
Framed as two general points to consider applicable to both new products
and any manufacturing changes to FDA-approved and cleared products, the
draft guidance provides both a dimensional aspect—“[w]hether an engineered
material or end product has at least one dimension in the nanoscale range
(approximately 1nm to 100 nm)”—and a behavioral aspect—“[w]hether an
engineered material or end product exhibits properties or phenomena,
including physical or chemical properties or biological effects, that are
attributable to its dimension(s), even if these dimensions fall outside the
nanoscale range, up to one micrometer.”269 Notably, the second point expands
the first dimensional aspect beyond the 100 nm range if the properties
exhibited are tied directly to its dimensions up to one micrometer (also called a
micron).270
Supporting its two points, the guidance also provides the Agency’s
rationale for the elements contained within the points to consider. These
largely recite the current state of knowledge of nanoscale properties and

265. Draft Guidance for Industry, supra note 24 (footnote omitted). For more information,
see also Q & As—Draft Guidance for Industry: Considering Whether an FDA-Regulated Product
Involves the Application of Nanotechnology, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
ScienceResearch/SpecialTopics/Nanotechnology/ucm258391.htm (last visited Jan. 22, 2012);
Press Release, U.S. Food & Drug Admin., FDA Takes ‘First Step’ Toward Greater Regulatory
Certainty around Nanotechnology (June 9, 2011), available at http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm258377.htm.
266. Draft Guidance for Industry, supra note 24.
267. Id.
268. OFFICE OF SCI. & TECH. POLICY ET AL., EXEC. OFFICE OF THE PRESIDENT,
MEMORANDUM FOR THE HEADS OF EXECUTIVE DEPARTMENTS AND AGENCIES: POLICY
PRINCIPLES FOR THE U.S. DECISION-MAKING CONCERNING REGULATION AND OVERSIGHT OF
APPLICATIONS OF NANOTECHNOLOGY AND NANOMATERIALS (2011), available at
http://www.whitehouse.gov/sites/default/files/omb/inforeg/for-agencies/nanotechnology-regula
tion-and-oversight-principles.pdf.
269. Draft Guidance for Industry, supra note 24.
270. Id.
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phenomena as the underpinnings of the two points.271 Specifically, the FDA
distinguishes the “deliberate manipulation and control of particle size” of an
engineered material or end product from the natural functioning at the
nanoscale, identifies the traditional bounds of the nanoscale encompassing
1nm to 100nm as serving merely as “a first [dimensional] reference point” for
industry, highlights the relationship between size and physical and chemical
properties as important for questions of safety and efficacy, and explains the
broadening of dimensions of “nanoscale” up to one micrometer as linking to
the use of agglomerates and aggregates that may coat or functionalize a
product.272
4.

Public Input

The FDA has also utilized requests for public comments in order to gather
information on the scientific aspects of nanotechnology. The FDA has held
several public meetings: October 2006 to aid in developing the
Nanotechnology Task Force Report;273 September 2008 to gather information
to assist the Agency in implementing recommendations laid out in the
Nanotechnology Task Force Report;274 and September 2010 to solicit data and
information on biocompatibility assessment of diagnostics and devices that
include nanomaterials.275 The FDA also maintains materials for the public on
its web page regarding nanotechnology.276
5.

Research Efforts

The FDA as an agency does not see much investment for basic research;277
however, the FDA is encouraging nanotechnology research in a number of
areas in order to inform agency decisions. The FDA is collaborating with the
NIH as part of the National Toxicology Program to address specific product

271. Id.
272. Id. (emphasis added).
273. Food and Drug Administration-Regulated Products Containing Nanotechnology
Materials; Public Meeting, 71 Fed. Reg. 46,232 (Aug. 11, 2006).
274. Consideration of FDA-Regulated Products That May Contain Nanoscale Materials;
Public Meeting, 73 Fed. Reg. 46,022 (Aug. 7, 2008).
275. Public Workshop on Medical Devices and Nanotechnology: Manufacturing,
Characterization, and Biocompatibility Considerations, 75 Fed. Reg. 51,829 (Aug. 23, 2010).
276. Nanotechnology, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ScienceResearch/
SpecialTopics/Nanotechnology/default.htm (last updated Sept. 28, 2011).
277. The FDA does support research and development for Orphan Products, but does not
itself conduct nanoresearch aside from some research within the individual centers on
characteristics of nanomaterials and processes. FDA Nanotechnology Regulatory Science
Research Categories, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ScienceResearch/Special
Topics/Nanotechnology/ucm196697.htm (last visited Jan. 22, 2012).
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concerns.278 The National Cancer Institute’s Nanotechnology Characterization
Laboratory, together with the FDA and the National Institute of Standards and
Technology, is conducting “preclinical efficacy and toxicity testing of
nanoparticles” in an effort to identify appropriate standards for molecular-sized
cancer drugs.279 The FDA has identified its areas of interest, such as risk
characterization based on physical and chemical properties, in vitro and in vivo
models to assist in predictions of human response to exposure, quantification
methods, measures of adsorption and transport in the human body, and
relationships between nanomaterial properties and the human body in terms of
uptake via the skin, lungs, and gastrointestinal tract.280
The FDA also boasts several public-private partnerships, including a
partnership with Johns Hopkins University and the Houston-based Alliance for
NanoHealth (“ANH”). The objectives of the collaboration with Johns Hopkins
are laid out as development of relationships for training and outreach and
development of collaboration among government and academia.281 The ANH
collaboration aims to “help speed development of safe and effective medical
products in the emerging field of nanotechnology,” which entails the FDA and
the ANH “work[ing] to expand knowledge of how nanoparticles behave and
affect biologic systems, and to facilitate the development of tests and processes
that might mitigate the risk associated with nanoengineered products.”282
While only an initial foray into oversight of nanotechnology by the FDA,
these moves reflect an incremental and coordinated effort among various FDA
Centers, including the CDER, CBER, CDRH, and the Center for Food Safety
and Nutrition (“CFSAN”) on issues with nanotechnology products.
IV. MOVING FORWARD—ASSESSING OVERSIGHT OPTIONS FOR EMERGING
NANOTECHNOLOGY COMBINATION PRODUCTS
The previous two sections illustrate the growing importance of
nanotechnology in the spectrum of drug, device, and biological applications
reviewed by the FDA. They also highlight the current uncertainty surrounding
how to appropriately regulate these products. As previously discussed, the
FDA first categorizes such products as a drug, device, or biologic and only
This categorization
then applies safety and efficacy requirements.283

278. See Partnerships: Federal, NAT’L TOXICOLOGY PROGRAM, http://ntp.niehs.nih.gov/go/
219 (last updated Nov. 3, 2004).
279. See Nanotechnology Characterization Lab, NAT’L CANCER INST., http://ncl.cancer.gov/
(last visited Nov. 30, 2011).
280. FDA Nanotechnology Regulatory Science Research Categories, supra note 277.
281. Nanotechnology Partnerships at FDA, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/
ScienceResearch/SpecialTopics/Nanotechnology/ucm208110.htm (last visited Jan. 22, 2012).
282. Id.
283. See supra Part II.
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determines whether the product will be subject to the most rigorous safety and
efficacy measures (NDAs for new drugs, PMAs for highest risk medical
devices, and BLAs for biologics) or whether it will be subject only to measures
of bioequivalence, substantial equivalence, or biosimilarity. As previously
noted, it appears most nanodrugs are entering the market through the
premarket approval process requiring safety and efficacy (although some have
proceeded to market on an accelerated basis based on promise for treatment of
life-saving or serious diseases), while most nanomedical devices have been
cleared through the less rigorous 510(k) process requiring only a showing of
substantial equivalence to a predicate device.284 Biologics have been subject to
safety and efficacy testing as set out in the PHSA; as described in Parts II.C
and D, it remains to be seen how the biosimilars pathway will unfold. The
regulatory pathways are becoming troublingly Byzantine. As is described
above, the discontinuities and silo effects in the current system pose real
concerns for long-term safety.
This section urges that the FDA utilize increased data gathering,
monitoring and tracking of nano-specific features and outcomes, as well as
strengthened collaborative approaches within the Agency, to bolster its
treatment of nanotechnology.
While not urging application of the
precautionary principle, this Article does argue that the FDA can, and should,
be doing more to address the uncertainties and safety concerns. This section
classifies suggestions for change into several areas: first, implementing general
coordination among agencies at the federal level; second, the possibility of
organizational restructuring within the FDA; and third, necessary regulatory
and policy changes within the FDA to address issues of safety and monitoring
of approved nanoproducts.
A.

The Need for a Strong Nanotechnology Coordinating Entity

In order for any collaborative model to succeed, a strong coordinating
entity must be created to facilitate efforts at assessing and adapting oversight
of nanotechnology among federal, state, and local agencies. The presence of a
well-funded national coordinating entity for contemplation of nanotechnology
oversight would assist in synthesizing and applying the emerging findings
regarding nanotechnology characterization, measurements, and risk assessment
and would lead a more unified, and unifying, approach to development of
mechanisms of oversight for emerging nanotechnologies. This is not to
suggest, as some esteemed scholars have, that in order to effectively deal with
nanotechnology Congress needs to set up a singular federal agency to regulate

284. See supra Part II.B.
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all nanotechnology products.285 This vision merely urges more collaboration
among agencies wrestling with oversight generally, and regulation and policy
specifically, in the area of nanotechnology.
The most promising entity within the federal government to serve this role
is the NNI. Created in 2000, and situated within the framework of the National
Science and Technology Council as a national coordinating entity for
nanotechnology research, development and education, the NNI has been the
federal vehicle for extensive mobilization and allotment of nanotechnology
funding.286 The NNI, which serves as coordinating entity for agencies dealing
with nanotechnology, does not have a specific mission or aim involving legal
and policy coordination. Although it fosters collaborative efforts in research
and education among the agencies, none of the almost ten billion dollars spent
on the NNI from 2001–2009287 has been devoted to tackling perhaps the most
challenging problem facing these regulatory agencies: how to regulate and
oversee the products resulting from this massive national investment.
The NNI does currently have a Nanotech Environmental and Health
Implications Working Group that “provides a forum for focused interagency
collaborations on EHS [environmental, health, and safety implications] and
leadership in establishing . . . the EHS research agenda, in addition to
communicating EHS information between NNI agencies and to the public.”288
Likewise, the National Nanotechnology Initiative Amendments of 2009289
provide multiple subgroups under the OSTP for research coordination
regarding environment, health and safety, and public engagement.290 Either a
separate oversight-specific subgroup could be created or these existing
subgroups could be more effectively utilized to address oversight and policy
questions.
Unfortunately, Congress and the NNI missed the opportunity to institute
such an oversight-contemplating arm as part of the ten-year renewal of the
initiative. The NNI recently asked for public comment on its Strategic Plan for

285. J. CLARENCE DAVIES, WOODROW WILSON INT’L CTR. FOR SCHOLARS, OVERSIGHT OF
NEXT GENERATION NANOTECHNOLOGY 25 (Project on Emerging Nanotechnologies, PEN 18,
2009), available at www.nanotechproject.org/process/assets/files/7316/pen-18.pdf.
286. What is the NNI?, NAT’L NANOTECHNOLOGY INITIATIVE, http://www.nano.gov/aboutnni/what (last visited Nov. 30, 2011).
287. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., NAT’L SCI. & TECH. COUNCIL, THE
NATIONAL NANOTECHNOLOGY INITIATIVE: RESEARCH AND DEVELOPMENT LEADING TO A
REVOLUTION IN TECHNOLOGY AND INDUSTRY: SUPPLEMENT TO THE PRESIDENT’S 2009 BUDGET
7 (2008).
288. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., supra note 60, at 35.
289. S. 1482, 111th Cong. (2009).
290. Gurumurthy Ramachandran et al., Recommendations for Oversight of
Nanobiotechnology: Dynamic Oversight for Complex and Convergent Technology, 13 J.
NANOPARTICLE RES. 1345, 1360 (2011).
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the 2011 fiscal year, including targeted aims of “foster[ing] the transfer of new
technologies into products for commercial and public benefit” and
“responsibly translating . . . knowledge [of the fundamental scientific science]
into practical applications.”291 In February, the NNI published its 2011
Strategic Plan, highlighting four goals: advancing a world-class
nanotechnology research and development program; fostering the transfer of
new technologies into products for commercial and public benefit; developing
and sustaining educational resources, a skilled workforce, and the supporting
infrastructure and tools to advance nanotechnology; and supporting the
responsible development of nanotechnology.292 While the NNI’s fourth goal
alludes generally to public health and the ethical, legal, and social implications
of nanotechnology development, it does not include the development of
collaborative structures to wrestle with questions of oversight raised by
nanotechnology and the importance of partnering evolving scientific
information into regulatory decisions and frameworks of the federal
agencies.293
However, as is typically the case with emerging technologies where federal
agencies are faced with scientific uncertainty and a lack of assessment
measures, large-scale coordination is often cumbersome due to differences in
statutory authority, regulatory missions, resources, priorities, and various other
factors. Feasibility is a limiting factor for such coordination.
B.

Restructuring the FDA

Congress and the FDA have endured long-standing complaints that the
categorical statutory and regulatory approach has caused a silo effect among
product areas depending largely on definition through amendments to the
FDCA spurred by reactions to large-scale events threatening public health and
safety.294 While Congress could contemplate the creation of a nanotechnology
specific Center or Office within the FDA, this would exacerbate the silo effect
by further segregating products based on definitional and categorical aspects.
A more workable model would be adjustments within the FDA by the
Commissioner to foster increased collaboration among the CDER, CBER, and
CDRH perhaps drawing on the established multi-center Nanotechnology Task
291. NNI Strategic Plan 2010; Request for Information, 75 Fed. Reg. 38,850, 38,850 (July 6,
2010).
292. SUBCOMM. ON NANOSCALE SCI., ENG’G, & TECH., supra note 60, at 23–32.
293. Id. at 30–32. One scholar has specifically urged President Obama to strengthen the
oversight role of the NNI and separate it from the promotional role of the NNI in his assessment
of the current status of oversight relevant to nanotechnology. See J. CLARENCE DAVIES,
WOODROW WILSON INT’L CTR. FOR SCHOLARS, NANOTECHNOLOGY OVERSIGHT: AN AGENDA
FOR THE NEW ADMINISTRATION 8–9 (Project on Emerging Nanotechnologies, PEN 13, 2008),
available at www.nanotechproject.org/process/assets/files/6709/pen13.pdf.
294. Foote & Berlin, supra note 11, at 623.
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Force. Such reorganization will be difficult given the current docket in front of
the FDA, but the Agency should nonetheless pursue changes in policy that are
within its mandate and authority from Congress. Although feasibility of a
national coordinating body for nanotechnology legal and regulatory issues and
FDA restructuring suffer from inevitable hurdles, the following two
subsections suggest a variety of actions that the FDA could implement to
initiate the process for improved information-gathering regarding
nanomedicine products at the individual product review and approval stage.
C. Uniform Information-Gathering Frameworks
Perhaps the most critical steps to address nanotechnology involve the
reassessment of concepts and measurements of safety utilizing the existing
statutory and regulatory toolkit available. Nanotechnology invariably raises
new questions for the FDA’s risk versus benefit quantification and assessments
due to lack of information regarding risk and public health effects. As
discussed in Part I.B, large-scale scientific uncertainty remains regarding short
and long-term effects, including toxicity, effect of various exposure routes and
routes of administration, possible unintended effects on non-target areas given
the ability of nanoparticles to cross the blood-brain barrier, and interaction of
various nanoparticles and nanomaterials within the human body. Faced with a
dearth of information regarding whether nanoparticles and nanomaterials have
novel toxicological effects and would thus demand different measures to
assure safety, the FDA has chosen to proceed to regulate based on existing
frameworks, taking some small initial steps to gather drug-specific information
via the internal MaPP detailed in Part III.C.2 and presenting considerations for
industry as detailed in Part III.C.3.
The existing statutory and regulatory scheme under which the FDA
operates provides it with sufficient authority over nanomedicine products
falling into the categories of drugs, medical devices, and biologics to develop
nano-specific rules and regulations according to established administrative
procedures.295 The problem turns on determining whether and to what extent
nanoproducts warrant additional nano-specific rules or regulations. In order to
inform this determination, the FDA needs to gather and assess more
information. While several modifications to the process would enhance the
FDA’s oversight and serve to gather much-needed information to allow the
FDA to make such determinations, core concerns remain regarding the
expertise necessary to assess safety and efficacy data, how to balance potential
novel risks and benefits, and how to monitor possible short-term and long-term
effects of nanomedicine products directly attributable to the nanoscale

295. Initial suggestions to improve FDA oversight of nanotechnology are presented by the
author in Ramachandran et al., supra note 290.
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properties. Although the FDA has broad statutory authority to require premarket and post-market data submission for these three product areas,296 the
FDA currently lacks the research budget and personnel to initially identify the
amount and type of information to request and subsequently how to assess that
data.297 The nascent state of understanding of properties and characterization
of nanomaterials and nanoparticles, particularly within the human body, poses
a major problem for the FDA.
1.

Full-Scale Safety and Efficacy Requirements

As a threshold matter, the FDA should set forth regulations or policy
indicating that nanotechnology products are subject to full-scale safety and
efficacy requirements for the requisite product categories (i.e., drug, medical
device, biologic) until there have been considerable research studies
undertaken that examine the range of uncertainties and unknowns. Where
subject to the less rigorous approval pathways, there is concern that
nanomedicine products may not satisfy traditional measures of equivalence (or
similarity) that the FDA employs to deem one product as having the same
safety profile because of the unique characteristics and properties exhibited at
the nanoscale. This approach is akin to the OCP’s decisions involving
innovations that raise novel questions for regulation in the realm of
combination products and sponsor requests for designation.298 This also
responds to current controversy regarding the inadequacy of the 510(k)
clearance process for medical devices and the successful completion of Phase
IV studies for drugs approved via the Fast Track or accelerated process based
on promise for treatment of life-threatening or serious diseases.
Once the FDA has amassed a significant amount of information pursuant
to the suggestions in Section IV.C.2 below, conclusions about continuance of
such a nano-specific channeling into the most rigorous approval pathway can
be based on robust scientific and technical information. The FDA should use
the nano-specific information gathered across the three Centers in joint
considerations of whether to continue to require the full extent of safety and
efficacy data by requiring a nano generic version of a non-nano pioneer drug to
go through full NDA process (or a nano follow-on biologic of a pioneer to
require a full BLA process), or at least require nano-specific information to be
gathered in post-market studies; not allowing medical device products
incorporating nanomaterials to be substantially equivalent to a predicate device
unless that predicate device has substantially equivalent nanomaterials or
nanoproperties (this goes to the scope of the “different technological

296. See supra Part II.A–C.
297. TAYLOR, REGULATING THE PRODUCTS OF NANOTECHNOLOGY, supra note 212, at 45–
47.
298. 21 C.F.R. §§ 3.1, 3.7 (2010).
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characteristics” that nonetheless pose no additional threat to safety or efficacy
phrase within the statute); and requiring all nanoproducts to proceed through
the BLA process rather than allowing measures of biosimilarity or
interchangeability to factor into the process.
2.

Information-Gathering Mechanisms

Even if the FDA does not implement policy requiring full-scale safety and
efficacy for nanoproducts, the FDA should implement specific uniform
information-gathering mechanisms. The FDA should proceed in a parallel
manner among all Centers pertaining to nanomedicine products—CDER,
CBER, and CDRH. Memoranda of Understanding among these Centers would
help memorialize these parallel efforts, define key roles, interactions, and
ultimate coordination processes for nanomedicine. Information-gathering
efforts should be installed that are uniform for NDAs (drugs), BLAs
(biological products), and PMAs (medical devices). Within the scope of its
authority, the FDA should also mandate that the industry supply the nanospecific information so the burden of information collection does not lie
entirely with the FDA. The FDA can use the CDER’s recent MaPP to develop
language for other Center policies and procedures of tracking that information,
as well as to help identify the information to be required by industry. The
FDA should consider whether the information reported to clinical trial online
databases should include nano-specific information.
In appropriate
circumstances, the FDA should utilize relevant regulations and statutory
provisions to request post-market studies directed toward the nanoparticle or
property of the product, such as REMS and new safety information provisions
discussed in Section II.A.
To assist in this endeavor, the FDA needs to utilize its scientific advisory
network of experts; request information from scientists and the public in the
form of announcements in the Federal Register, public meetings, forums, and
other opportunities to identify relevant issues; and develop mechanisms to
collect, analyze, characterize, and mine this information. The FDA has begun
to do this, having sponsored several public meetings, urging research into
characterization and measurement methods, and initiating an internal process
in the CDER to begin tracking nanodrugs.299 However, this approach has been
piecemeal, with little coordination yet even among Centers within the FDA, let
alone collaboration with other federal agencies. It also fails to take advantage
of the FDA’s authority to request specific information about a product prior to
approval, or clearance of that product.
For those nanomedicine products already approved or cleared that were not
subject to the most rigorous pre-approval processes, the FDA should also

299. See supra Part III.
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request additional information from the manufacturer or sponsor in order to
track and assess those nanospecific properties and characteristics. Efforts
should also loop into other FDA Centers as well, including the CFSAN
(regulating foods, dietary supplements, and cosmetics) and the Center for
Veterinary Medicine.
CONCLUSION
The FDA engages in a delicate balance between protecting the public
health and safety and promoting advancements in medicine and health care.
Technological innovation often outpaces oversight by specialized scientific
federal agencies tasked with regulating the resulting products and processes.
Nowhere is this lag between innovation and regulatory response more
prevalent than the realm of nanotechnology, a spectrum of disciplines and
applications that integrates unique and novel properties. Relevant specifically
to the FDA is nanobiotechnology and nanomedicine, blending chemical,
mechanical, and biological properties in a way that stretches existing oversight
frameworks for drugs, medical devices, and biologics. While nanotechnology
raises problems for oversight, this Article has suggested several approaches for
the FDA to begin assessing and responding to the challenges. These
encompass a variety of coordinating and collaborative efforts coupled with the
use of authority in the context of increased information gathering from industry
and post-market monitoring.
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FIGURE 1: EXAMPLES OF FDA-APPROVED DRUGS UTILIZING NANOSCALE
PROPERTIES OR MATERIALS300
Product

Indications

Company

Formulation
Description

Original
Approval

Doxil

Ovarian cancer,
breast cancer, and
AIDS-related
Kaposi’s sarcoma

OrthoBiotech
Products, LP

Liposomal
doxorubicin

NDA
November 1995
(accelerated
approval)

DepoCyt

Lymphomatous
meningitis

Pacira

Liposomal
cytarabine

NDA
April 1999
(accelerated
approval)

Rapamune

Immunosuppressant
for prevention of
organ rejection in
renal transplant
patients (13 &
older)
Prevents nausea and
vomiting induced
by chemotherapy

Wyeth

Nanocrystalline
sirolimus

NDA
September
1999

Merck & Co.

Nanocrystalline
aprepitant

NDA
March 2003

Estrasorb

Topical soy-based
estrogen therapy for
treatment of
menopausal hot
flashes

Graceway

Estradiol in micellar
nanoparticles

NDA
October 2003

Abraxane

Breast cancer

Abraxis
Bioscience

Albumin-bound
paclitaxel

NDA
January 2005

Emend
(Fosaprepitant
Dimeglumine)

Prevents nausea and
vomiting induced
by chemotherapy

Merck & Co.

Lyophilized
fosaprepitant
dimeglumine

NDA
January 2008

Emend
(Aprepitant)

300. Information adapted from Paradise et al., supra note 14, at 410–17; Paradise, supra note
235, at 203–207.
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FIGURE 2: EXAMPLES OF FDA-APPROVED MEDICAL DEVICES UTILIZING
NANOSCALE PROPERTIES OR MATERIALS301
Formulation
Description
Silica-zirconia
nanoparticle filler

Original
Approval
Information
510(k)
January 2003

Product
Simile NanoHyrbid
Composite

Indications
Dental material

Company
Pentron
Laboratory

Nano-Ticrown

Dental material

Nano-Write
Corporation

Nanostructured
titanium/titanium
nitride material

510(k)
June 2003

TiMesh

Tissue
reinforcement and
hernia repair

GfE
Meizintechnik

Titanium
nanomaterial

510(k)
September
2003

Vitoss

Bone graft
substitute

Ortho Vita,
Inc.

Nanoparticles

510(k)
December 2003

Prime & Bond
NT

Dental bonding
agent

Dentsply
International

Nanometer sized
bonding agent

510(k)
February 2005

ACTICOAT

Antimicrobial
wound dressing for
burns, graft sites,
and ulcers

Smith &
Nephew

Utilizes Silcryst
silver nanocrystals
technology
(licensed from
NuCryst)

510(k)
April 2005

On-Q Silver
Soaker

Antimicrobial
catheter

i-Flow
Corporation

Treated with
SilvaGard (licensed
from Acrymed)

510(k)
November 2005

AcryDerm

Antimicrobial
wound gel

Acrymed, Inc.

Polyurethane
adhesive using
SilvaGard silver
nanoparticle
technology

510(k)
October 2006

Silcryst

Antimicrobial
wound cream

NuCryst

Nanocrystalline
silver cream

510(k)
July 2007

ASAP Wound
Dressing

Topical cream

American
Biotech Labs

Coated with
nanosilver

510(k)
April 2009

301. Paradise et al., supra note 14, at 415–17; Press Release, American Biotech Labs,
American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product (Apr. 14,
2009), available at http://www.reuters.com/article/2009/04/14/idUS215860+14-Apr-2009+PRN
20090414.
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